UNIVERSITY OF BIRMINGHAM University of Birmingham Research at Birmingham

An evaluation of the mental health impact of SARS-CoV-2 on patients, general public and healthcare professionals

Phiri. Peter: Ramakrishnan, Rema; Rathod, Shanaya; Elliot, Kathryn; Thayanandan, Tony; Sandle, Natasha; Haque, Nyla; Chau, Steven Wh; Wong, Oscar Wh; Chan, Sandra Sm; Wong, Evelyn Ky; Raymont, Vanessa; Au-Yeung, Sheena K; Kingdon, David; Delanerolle, Gavathri

DOI:

10.1016/j.eclinm.2021.100806

License: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Phiri, P, Ramakrishnan, R, Rathod, S, Elliot, K, Thayanandan, T, Sandle, N, Haque, N, Chau, SW, Wong, OW, Chan, SS, Wong, EK, Raymont, V, Au-Yeung, SK, Kingdon, D & Delanerolle, G 2021, 'An evaluation of the mental health impact of SARS-CoV-2 on patients, general public and healthcare professionals: A systematic review and meta-analysis', *EClinicalMedicine*, vol. 34, 100806. https://doi.org/10.1016/j.eclinm.2021.100806

Link to publication on Research at Birmingham portal

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

FISEVIER

Contents lists available at ScienceDirect

EClinicalMedicine



journal homepage: https://www.journals.elsevier.com/eclinicalmedicine

Research Paper

An evaluation of the mental health impact of SARS-CoV-2 on patients, general public and healthcare professionals: A systematic review and meta-analysis

Peter Phiri^{a,b,*}, Rema Ramakrishnan^c, Shanaya Rathod^a, Kathryn Elliot^a, Tony Thayanandan^d, Natasha Sandle^d, Nyla Haque^d, Steven W.H. Chau^e, Oscar W.H. Wong^e, Sandra S.M. Chan^e, Evelyn K.Y. Wong^f, Vanessa Raymont^d, Sheena K. Au-Yeung^d, David Kingdon^g, Gayathri Delanerolle^d

^a Southern Health NHS Foundation Trust, Research and Development Dept., Clinical Trials Facility, Moorgreen Hospital, Southampton SO30 3JB, UK

^b Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Aldermoor Health Centre, Southampton SO16 5ST, UK

^c Nuffield Department of Women's and Reproductive Health, University of Oxford, UK

^d Oxford Brain Health Clinical Trials Unit, Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford OX3 7JX, UK

^e Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong

^f Department of Psychiatry, North District Hospital, Hong Kong

^g University Department of Psychiatry, Academic Centre, College Keep, University of Southampton, UK

ARTICLE INFO

Article History: Received 18 December 2020 Revised 5 March 2021 Accepted 5 March 2021 Available online 6 April 2021

Keywords: Sars-CoV-2 COVID-19 Healthcare professionals Health Mental health and physical wellbeing

ABSTRACT

Background: The global impact of COVID-19 pandemic continues to affect the lives of billions of people with recurrent waves. Healthcare systems are struggling to manage pre-existing patient care and recurring covid-19 demands. As a result, we evaluated the mental health impact using systematic review and meta-analysis. Methods: A comprehensive search was undertaken from April 2020 to 22nd January 2021 using multiple electronic databases. A systematic review protocol was developed and published on PROSPERO registration; CRD42020181481. A random-effects model was used to compute pooled estimates of anxiety, depression, PTSD, insomnia and suicidal thoughts.

Findings: Our search yielded 11,295 studies and of those 287 met the inclusion criteria. The meta-analysis of 206 studies revealed minimal differences in prevalence of anxiety, depression, and PTSD among HCPs compared with the public during the pandemic but higher prevalence of suicidal thoughts/ideation or self-harm (11% vs 5.8%) and lower prevalence of wellbeing (28.2% vs 52.6%) among the public compared to HCPs.

Interpretation: The pandemic has led to a high mental health burden especially amongst HCPs and higher suicidal ideation and lower wellbeing in general public which warrants further investigation and management globally. These findings highlight an emerging critical public health issue that requires urgent solutions. © 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

The coronavirus disease 2019 (COVID-19) could be considered as the most complex pandemic during the 4th industrial revolution. The pandemic and lockdown has caused an unprecedented sense of fear and anxiety across the globe. This catastrophic phenomenon has resulted in both short- and long-term mental health (MH) and psychosocial implications. A recent review reported adverse psychological effects, which included post-traumatic stress (PTSD) symptoms, confusion and anger to be some of the concerns associated with the current pandemic [1]. An abundance of cross-sectional surveys have demonstrated a high prevalence of depression and anxiety. For example, Rathod and colleagues [2] reported from a threeweek analysis of their global survey, healthcare professionals recorded a high proportion of mild depression and anxiety.

Prior to the COVID-19 pandemic, a staff survey conducted in the UK's National Health Service (NHS) in 2019 found 40.3% of healthcare professionals (HCP) reported work-related stress in the previous 12 months that led to issues around wellbeing [3]. This proportion has steadily been increasing, with the latest survey from 2020 stating 33% of frontline doctors and over a quarter of GPs are suffering from

https://doi.org/10.1016/j.eclinm.2021.100806

2589-5370/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

^{*} Corresponding author at: Southern Health NHS Foundation Trust, Research and Development Dept., Clinical Trials Facility, Moorgreen Hospital, Southampton SO30 3JB, UK.

E-mail address: P.Phiri@soton.ac.uk (P. Phiri).

Research in context

Evidence before this study

Mental health impact associated studies exploring the impact of SARS-CoV-2 have been lacking. The likelihood of these studies increasing in the near future is limited, partly due to limited funding availability for mental health associated research in comparison to other clinical areas, as well as the recurring outbreaks which demonstrates that the pandemic is still here and therefore, the mental health impact is equally recurring. Previous systematic reviews have reported primarily on mental health symptoms using different methodologies that demonstrated limited evidence based robustness that could provide better insight to clinicians, clinical researchers and policy makers.

Added value of this study

The added value of this study is based on the evidence based methodology used in the context of a systematic review to evaluate clinical outcomes in mental health. To our knowledge, previous systematic reviews and meta-analysis published do not focus on the impact and array of mental health outcomes using multiple cohorts. Whilst we obtained similar prevalence of anxiety, depression, PTSD, and insomnia among healthcare professionals and the general public, a new development in this study is that there appears to be higher prevalence of suicidal thoughts/ideation or self-harm (11% vs 5.8%) and lower prevalence of wellbeing (28.2% vs 52.6%) among the public compared to healthcare professionals which had previously not been reported. As a result, the clinical significance associated with anxiety, depression and PTSD provide invaluable information to health care services in particular to Mental Health care providers to plan clinical management strategies short, medium and long-term.

Implications of all the available evidence

The prevalence varies between healthcare professionals, patients and the public. However, a common theme that would support global and national healthcare systems would be the development of a mental healthcare strategy for pandemicrelated interventions/ treatments and service provision both short, medium and long-term use.

Additionally, self-reporting and subsequent self-assessment using digital interventions could provide support to both patients and organizations to prepare for future pandemics, given the most commonly reported symptomatologies appear to be anxiety and depression. This has both research and clinical implications for current and future patients, clinicians as well as researchers.

anxiety, depression, stress, emotional distress, occupational burnout and/or other mental health conditions [4]. Therefore, it could be hypothesized based on the current research data and clinician reported outcomes, available, these conditions may have been heightened during the pandemic.

The current psychological impact of frontline staff appears to be similar to those recorded during the SARS outbreak in 2003 [5]. Wu and colleagues [5] reported that 549 frontline HCPs of the SARS pandemic reported consistent PTSD symptomatologies over the course of their 3-year study. Further literature has highlighted the COVID-19 pandemic is an event that is unmanageable and unfamiliar, increasing the likelihood of individuals developing PTSD due to the trauma experienced during this ongoing pandemic [6–8]. Exposure to traumatic disasters is not limited to pandemics, it also includes

alternative large scale disasters like the 9/11 attacks. An extensive body of literature concluded that since the 9/11 attacks in the past 10 years reported that the prevalence of PTSD among individuals who experienced a high level of exposure to 9/11 was significant [9]. This research coincides with the hypothesis that the greater "dose" of trauma healthcare professionals face during the COVID-19 pandemic leads to a greater adverse effect psychologically.

As per the current reports, COVID-19 first emerged in December 2019, when a cluster of patients with pneumonia of unknown cause in Wuhan were recognized. Furthermore, it has been continuously observed that a significant proportion of patients recovering from severe COVID-19 disease may develop long term and persistent psychological symptoms, either as direct result of the virus or as a result of their experiences of the illness including trauma, treatment and long-term health implications [10]. Some may also present with varying degrees of communication and cognitive impairment [11]. It is now widely recognized that respiratory symptoms of COVID-19 are extremely heterogeneous, ranging from minimal symptoms to significant hypoxia with acute respiratory distress syndrome (ARDS) [12] whilst the pathophysiology remains relatively unknown. The definition of asymptomatic, mild, moderate, severe and critical is summarized in Table 1.

A report from Wuhan mentioned that the time between the onset of symptoms and the development of ARDS was as short as nine days, suggesting that the respiratory symptoms could progress rapidly [13]. Although, further research would need to be conducted to evaluate these findings comprehensively, as there could be a MH impact due ARDS as well. Current medical management is largely supportive with no targeted therapy available as with any virus, which remains dormant until the assimilation with the host. Several drugs including lopinavir-ritonavir, remdesivir, hydroxychloroquine, and azithromycin have been tested in clinical trials [14-15] although, currently there is no evidence to suggest a definitive treatment strategy. However, early interim analysis from these trials show initial aptitude for immune-suppression [16]. To date several vaccines have been approved globally for emergency treatment of the virus including Oxford-AstraZeneca, Pfizer- Biontech, Moderna, etc. However, the MH implications associated with the population pre and post vaccination for example remains unclear.

As of 22nd February 2021, SARS-CoV-2 has affected more than 219 countries resulting in 110,974,862 confirmed cases and 2460,792 deaths and 225,839 new cases [17]. A summary of prevalence and mortality rates by country can be found in Table 2. However, caution must be taken when interpreting this data as there are multi-factorial deficits to the current published datasets with regards to incidence and mortality reporting. These may not include primary, secondary and tertiary care healthcare settings, as well as those that were unreported due to mild symptomatology.

Whilst the current pandemic is the fifth documented within the last few centuries, there have been many others prior to the most recent outbreaks. But there has been a lag in both scientific theory and evidence-based discussions around pandemics. Therefore, it is critical to now try and understand the cognitive and psychological impact of the virus, as well as the 'real-world' psychological impact of the pandemic on healthcare professionals, patients and the general public. This is especially so given the rapid spread of the pandemic, pathogenicity, with antiviral treatments and vaccine development rightly being the primary focus.

2. Methods

An evidence synthesis methodology was developed with a systematic protocol that was peer reviewed and registered with PROS-PERO database (CRD42020181481) [67]. The reporting of the systematic review and meta-analysis was conducted as per PRISMA guidelines.

Table 1
Classification of COVID-19 symptomology.

AsymptomaticCOVID nucleic acid test positive. Without any clinical symptoms and signs and the chest imaging is normalMildSymptoms of acute upper respiratory tract infection (fever, fatigue, myalgia, cough, sort throat, runny nose, sneezing) or digestive (nausea, vomiting, abdominal pain, diarrhea)ModeratePneumonia (frequent fever, cough) with no obvious hypoxemia, chest CT with lesionsSeverePneumonia with hypoxemia (SpO2 <92%)CriticalAcute respiratory distress syndrome (ARDS), may have shock, encephalopathy, myocardial injury, heart failure, coagulation dysfunction and acute kidney injury		
Moderate Pneumonia (frequent fever, cough) with no obvious hypoxemia, chest CT with lesions Severe Pneumonia with hypoxemia (SpO2 <92%)	Asymptomatic	1 5 5 1
emia, chest CT with lesions Severe Pneumonia with hypoxemia (SpO2 <92%) Critical Acute respiratory distress syndrome (ARDS), may have shock, encephalopathy, myocardial injury, heart failure, coagula-	Mild	fatigue, myalgia, cough, sort throat, runny nose, sneezing)
Critical Acute respiratory distress syndrome (ARDS), may have shock, encephalopathy, myocardial injury, heart failure, coagula-	Moderate	
encephalopathy, myocardial injury, heart failure, coagula-	Severe	Pneumonia with hypoxemia (SpO2 <92%)
	Critical	encephalopathy, myocardial injury, heart failure, coagula-

2.1. Search strategy and selection criteria

A comprehensive, systematic search was conducted for published articles using multiple databases of PubMed, Proquest, EBSCOhost and ScienceDirect from April 2020 to 22nd January 2021. Suitable articles were selected in two stages using the PICO (Population/Participants, Intervention(s), Comparison, Outcome) strategy. We included studies comprising empirical, qualitative or quantitative evidence on COVID-19 and mental health in the patients, general public and healthcare professional population. We excluded editorials, commentary, letters to the editor, simple reviews and studies that did not have the outcomes measures specified in the protocol.

Table 2

Prevalence and mortality rate of COVID-19 by country.

2.2. Study selection and data extraction

First, the title and abstract of each article were screened independently by investigators (KE, TT, SA-Y). If there was a consensus that an article was not suitable for inclusion the article was excluded. Next. the full text articles were screened independently by two investigators and included if all authors agreed. The following information was extracted from all included studies, citation details, methods used to establish processes and corresponding characteristics, key findings, limitations and conclusions reported. Any differences of opinion or quires were reviewed and resolved by (PP &GD). The authors were not blinded with respect to the article's authors or the journal in which it was published. The investigators organized the articles into three categories, namely: healthcare professionals, patients and general public. Two investigators extracted predefined clinical variables (summarized in supplementary Table 1). Each variable was then inspected to understand if it was a pre-existing condition, direct result of COVID, if treatment was received and the symptomology. Investigators (GD& PP) independently cross-checked data retrieved from each article as per our refinement protocol (supplementary Fig. 1).

2.3. Risk of bias (quality) assessment

Majority of the studies included were cross-sectional. All literature retrieved were critically appraised on an individual basis using common variables. Independent reviewers appraised methodological quality and risk of bias according to the Newcastle-Ottawa Scale (NOS) that has validity for use in cohort studies Wells et al. [18] and

Country	Mortality Rate	Prevalence Rate	Total COVID-19 Tests	Definition of Mortality
China	4641	84,780	Unavailable	Not Provided
India	16,893	566,840	8.61 million	Cases with confirmed positive test for COVID-19 only. Not counting suspected cases
Italy	34,744	240,436	5.39 million	Any death of patient with COVID-19 that has a death caused by COVID-19
Singapore	26	43,661	414,396	WHO guidelines followed
South Korea	282	12,800	1.25 million	
Spain	28,355	249,271	3.64 million	Cases with confirmed positive test for COVID-19 only
United Kingdom	43,730	311, 965	7.33 million	WHO Guidelines followed although Dept of Health specified definition used; fatality where COVID-19 mentioned on death certificate.
England	39,187	160,587	2.29 million	Deaths included if the deceased had a positive test for COVID-19, however long after the test they died.
Scotland	2482	18,251	272,561	Deaths that have been registered with a confirmed lab diagnosis of COVID-19 in the 28 days prior to death
Wales	1510	15,743	182,303	Deaths of hospital or care home residents where COVID-19 has been confirmed with a lab diag- nosis or the clinician suspects this was the causative factor in the death
Northern Ireland	551	160,587	101,506	Deaths where the deceased had a positive test for COVID-19 and died within 28 days, whether or not COVID-19 was the causative factor
United States Japan	126,140 972	2.59 million 18,593	32.31 million 461,446	Fatality where COVID-19 mentioned on death certificate
New Zealand	22	1178	402,000	
Canada	8566	103,907	2.68 million	Numbers are collated from different provinces which all have own methodologies.
France	29,813	164,260	Unavailable	

the adapted version by Modesti et al. [19] was used for cross-sectional studies in meta-analyses. An eight item scale with three quality parameters (i) selection, (ii) comparability and (iii) outcome. We rated the quality of the studies (good, fair and poor) by allocating each domain with stars in this manner:

- A Good quality score was awarded 3 or 4 stars in selection, 1 or 2 in comparability, and 2 or 3 stars in outcomes
- A **Fair** quality score was awarded 2 stars in selection, 1 or 2 stars in comparability, and 2 or 3 stars in outcomes.
- A Poor quality score was allocated 0 or 1 star(s) in selection, 0 stars in comparability, and 0 or 1 star(s) in outcomes domain [18].

Following the application of the refinement protocol, 287 studies were evaluated, and their full text was reviewed to confirm the inclusion/exclusion criteria were met. The extraction of data had a specific focus on highlighting variables reported within the studies and any symptomologies reported within the three population groups, namely: patients, HCPs and the general public, in addition to providing an overall scientific justification for the inclusion of each study.

2.4. Outcomes

The following outcomes were included in the meta-analysis based on the availability of statistics reported by each study:

- Prevalence of anxiety, depression, PTSD, insomnia, suicidal thoughts/ideation, or self-harm and wellbeing among HCP and the public
- Prevalence of poor sleep quality and alcohol use among the public
- Clinical significance of the prevalence data identified
- Critical interpretive synthesis of common MH reported outcomes amongst HCPs and the general public

The outcomes for patients could not be synthesized for the metaanalysis; therefore, these are presented as narrative review only.

2.5. Statistical analysis

Estimates for studies that reported median and interquartile range were converted to mean and standard deviation before metaanalyses [20]. For studies that reported only mean (SD) or median (IQR) and no prevalence we employed Monte Carlo simulations to estimate the prevalence based on appropriate cut-off points for the tool used to measure the outcome. For this we assumed normality of the distribution. For each outcome, if a study reported estimates for multiple groups of healthcare professionals or the public, we combined these estimates into one estimate for that study. A randomeffect model was used to estimate pooled estimate of prevalence. We used the I² statistic to assess heterogeneity between the studies; values of 25%, 50%, and 75% were used to categorize the degree of heterogeneity into low, moderate, and high, respectively [21]. We investigated sources of heterogeneity by conducting stratified analyses by mean/median age (\leq 30 years vs >30 years), country, outcome measurement tool, and study quality. We also conducted sensitivity analyses by estimating the pooled prevalence after removal of studies for which the prevalence was calculated from simulations. Publication bias was assessed using visualization of funnel plots and Egger's test for estimates with a sample size ≥ 10 . We constructed funnel plots by study quality to examine if it contributed to publication bias. Meta-analyses were conducted using STATA version 14.0 (StataCorp, College Station, TX, USA). Statistical testing was conducted at a twotailed alpha level of 0.05.

2.6. Role of funding

KE, GD, and PP are supported by National Institute for Health Research (NIHR) Research Capability Funding (RCF) and by Southern Health NHS Foundation Trust and Oxford Brain Health Clinical Trials Unit. All of the study sponsors had no further role in the study design, data collection, analysis and interpretation of data; in the writing of the report and in the decision to submit the paper for publication.

3. Results

3.1. General characteristics

Our comprehensive literature search undertaken on April 2020 (up to 22nd January 2021) identified 11,295 articles of these (n = 287) met the inclusion criteria as shown in Fig. 1. Detailed descriptions of the studies included in this review are displayed in STable 1. This also includes provides NOS quality assessment scores of included studies.

3.2. Meta-analysis


For the meta-analysis we included 206 studies (83 in healthcare professionals, 134 among the public, and 11 studies in both these populations) with a sample size of 721,244 and mean/median age ranging from 15.3 to 71 years. About a third of the studies was conducted in China (n = 62) followed by U.S.A. (n = 18), the U.K. (n = 16), and Italy (n = 15) and nine were multinational.

There were 69, 66, 19, 17, four, and three studies included in the meta-analysis with prevalence data of anxiety, depression, PTSD, insomnia, suicidal thoughts/ideation or self-harm, and wellbeing among healthcare professionals, respectively. There were 102 studies included for anxiety, 105 for depression, 19 for PTSD, 14 for insomnia, six for poor sleep quality, ten for suicidal thoughts/ideation or self-harm, nine for wellbeing, and 11 for alcohol use among the public. There were 13 studies that reported mental health outcomes in patients; however, none of these could be harmonized or the number of studies for an outcome was too small for a meta-analysis.

Among healthcare professionals, the pooled prevalence of anxiety was 21.9% (95% CI: 18.7–25%) (Fig. 2) whereas this estimate was 22.4% (95% CI: 19.8 – 25%) among the public (Fig. 3). The estimates for depression were 23.4% (95% CI: 20.6–26.3%) (Fig. 4) and 22.6% (95% CI: 20.0–25.1%) (Fig. 5) among healthcare professionals and the public, respectively.

The prevalence for PTSD was 25.0% (95% CI: 18.9–31.2%) (Fig. 6A) for healthcare professionals whereas among the public this estimate was marginally lower at 23.2% (95% CI: 10.5-35.9%) (Fig. 6B). There was minimal difference in the prevalence of insomnia among healthcare professionals and the public (24% vs 23%) (SFig. 1A and B). In addition to this, about 39% of the public reported poor quality of sleep that was mostly measured using the Pittsburgh Sleep Quality Index (PSQI) questionnaire (SFig. 2). The prevalence of suicidal thoughts/ ideation or self-harm was 11% (95% CI: 6.4–15.7%) among the public (SFig.3B) whereas among healthcare professionals the estimate was 5.8% (95% CI: 4.7-7.0%) (SFig. 3A). The prevalence of higher wellbeing was higher among healthcare professionals (52.6%, 95% CI: 43.8-61.4%) (SFig. 4A) whereas among the public the prevalence was 28.2% (16–40.4%) (SFig. 4B). There was minimal difference in the prevalence of alcohol use among the public for increased (22.9%) and decreased (21.7%) alcohol use but the prevalence for no change in alcohol use was high at 52% (SFig.5).

The heterogeneity was high for all outcomes included in the meta-analysis.





3.3. Sensitivity and subgroup analysis

We were able to conduct sub-group analysis by mean/median age (\leq 30 years vs >30 years) for prevalence estimates of anxiety, depression, PTSD, and insomnia among healthcare professionals and the public. These analyses found insufficient evidence for heterogeneity by mean/median age for prevalence estimates of anxiety, depression,

PTSD, and insomnia among healthcare professionals (SFigs. 6, 8, 10, and 12). Among the public there was insufficient evidence to explain heterogeneity by mean/median age groups for anxiety and insomnia (SFigs. 7 and 13). However, there was evidence for heterogeneity by mean/median age (\leq 30 years vs >30 years) for depression (*P* value heterogeneity: 0.003) and PTSD (*P* value heterogeneity: 0.04) estimates (SFigs. 9 and 11). The prevalence of depression among the public was

6

P. Phiri et al. / EClinicalMedicine 34 (2021) 100806

		Percent (95% CI)
AlAteeg, D.A, 2020	i	17.13 (13.94, 20.72)
Alonso, J, 2020	11	22.50 (21.65, 23.37)
Antonijevic, J, 2020ª	LT	6.26 (5.15, 7.52)
Arac, S, 2020ª	[: _	56.57 (46.23, 66.50)
Azoulay, E, 2020		47.09 (40.11, 54.15)
Bahadir-Yilmaz, E, 2020ª	11-	■ 88.88 (87.15, 90.45)
Cai, Q, 2020	-	11.51 (9.74, 13.48)
Chew, N.W.S, 2020ª		7.95 (6.27, 9.90)
Chew, S.K, 2021		12.00 (7.84, 17.33)
Civantos, A.M., 2020		15.34 (10.18, 21.80)
Crowe, S, 2020	12	16.51 (10.09, 24.84)
Florin, M, 2020	12	14.59 (12.85, 16.47)
Francisco, S, 2020ª		11.47 (9.30, 13.94)
Giebel C, 2020		27.85 (22.03, 34.29)
Gorini, A, 2020		14.77 (12.13, 17.73)
Greenberg, N, 2021	13	19.04 (16.21, 22.13)
Havaei, F, 2021ª		11.10 (10.10, 12.16)
		35.73 (31.05, 40.63)
He, Q, 2020		
Hong, S, 2021	1	8.10 (7.33, 8.92)
Hummel, S, 2021		18.23 (15.24, 21.53)
Johnson, S.U, 2020		24.99 (22.99, 27.07)
Juan, Y, 2020		31.58 (27.33, 36.06)
Judith, A, 2020		18.27 (15.47, 21.35)
Kang, L, 2020 ^a		12.98 (10.95, 15.23)
Khamis, F, 2020		50.22 (43.59, 56.84)
Khanal, P, 2020		21.05 (17.47, 25.00)
Lai, J, 2020		44.63 (41.86, 47.43)
Li, X, 2020		35.56 (29.31, 42.19)
Liang, Y, 2020 ^a		3.56 (2.05, 5.71)
Liu, T, 2020 ^a		0.92 (0.49, 1.56)
Liu, Y, 2021		13.30 (11.34, 15.46)
Lu, W, 2020 ^a	T:	2.20 (1.61, 2.94)
Ma, Y, 2020		35.29 (19.75, 53.51)
Magnavita, N, 2020ª	•	15.56 (8.77, 24.72)
Mahyijari, N.A, 2020ª		6.67 (3.24, 11.92)
Mekonen, E, 2020	-	69.54 (64.01, 74.68)
Monterrosa-Castro, A, 2020		39.36 (35.18, 43.66)
Mosolova, E, 2020ª		6.79 (5.37, 8.45)
Mrklas, K, 2020		38.12 (35.58, 40.71)
Naser, A.Y, 2020		23.56 (21.15, 26.11)
Ni, M.Y, 2020	•	21.96 (16.61, 28.11)
Ning, X, 2020		16.34 (13.50, 19.51)
Pan, X, 2020	•	32.47 (25.94, 39.55)
Prasad, A, 2020	•	23.05 (18.73, 27.85)
Rapisarda, F, 2020ª	• •	2.07 (0.68, 4.77)
Rathod, S, 2020	•	8.20 (7.54, 8.88)
Riello, M, 2020	•	22.04 (19.59, 24.64)
Rossi, R, 2020		19.36 (17.29, 21.57)
Sahin, M.K, 2020	•	22.15 (19.53, 24.95)
Setiawti, Y, 2021		28.25 (22.44, 34.65)
Shetchter, A, 2020	•	23.83 (18.29, 30.11)
Shrestha, S.L, 2020	 +	24.75 (16.70, 34.33)
Sun, Y, 2020ª	• • •	0.37 (0.05, 1.34)
Suryavanshi, N, 2020		28.93 (22.71, 35.81)
Than, H.M, 2020		33.53 (26.54, 41.09)
Tiete, J, 2020		12.98 (10.49, 15.82)
Trumello, C, 2020	•	7.29 (5.52, 9.40)
Wanigasooriya, K, 2020		34.31 (32.49, 36.15)
Woon, L.S.C, 2020		8.02 (5.55, 11.13)
Wright, H.M, 2020	4	17.34 (14.32, 20.70)
Xiaoming, X, 2020		6.90 (6.38, 7.44)
Yang, S, 2020		50.00 (36.08, 63.92)
Youssef, N, 2020		10.74 (8.26, 13.66)
Zalzaid, E.H, 2020		16.10 (12.79, 19.87)
Zhang, C, 2020		44.72 (42.24, 47.23)
Zhang, L, 2020 ^a		1.59 (1.10, 2.21)
Zhang, U, 2020- Zhang, W-R, 2020a	Ĩ _ :	8.38 (7.11, 9.79)
Zhang, W-R, 2020 Zheng, R, 2020		32.58 (28.89, 36.43)
Zheng, Y, 2020 Zheng, Y, 2021	L	14.49 (10.00, 20.04)
LIGING, 1, 2021	17	21.85 (18.73, 24.96)
Overall (l ² = 99.7%, p<0.001)	Y	21.03 (10.73, 24.30)

Fig. 2. Forest plot of prevalence of anxiety among healthcare professionals. Note: aPrevalence calculated from mean and standard deviation using Monte Carlo simulation.

greater for \leq 30 years age group compared to >30 years age group (31% vs 18.4%) (SFig.9). Similarly, the prevalence of PTSD was higher among \leq 30 years compared to >30 years (49% vs 12.8%) (SFig. 11).

The analyses by country found insufficient evidence to explain the high heterogeneity found in the meta-analysis for anxiety and depression among healthcare professionals (SFigs. 14 and 16) and anxiety among the public (SFig.15). However, it revealed significant heterogeneity by country of study (P value _{heterogeneity}: <0.0001) (SFig. 17). For prevalence estimates of PTSD and insomnia there were insufficient number of studies to conduct stratified analyses, but Percent (95% CI

50.00 (45.56, 54.44

28.96 (26.26, 31.77) 5.45 (4.39, 6.68) 33.71 (31.26, 36.23) 22.00 (19.82, 24.31)

Publicathor
Aharon, A.A, 2021
Ahmed, M.Z, 2020
Alamri, H.S, 2020
Banna, H.A, 2020
Barzilay, R, 2020
Bauerle, A, 2020
Bendau, A, 2020
Cansel, N, 2021
Cao, W, 2020
Capasso, A, 2021
Casagrande, M, 2020*
Cellini, N, 2020
Cenat, J.M, 2021
Chen, S, 2020
Cheng, C, 2020
Creese, B, 2020
Dawel, A, 2020*
Duncan, G.E, 2020
Duong, K.N.C, 2020
Every-Palmer, S, 2020
Fancourt, D, 2021
Faulker, J, 2020
Ferrucci, R, 2020
Fisher, J.R.W, 2020
Franceschini, C, 2020
Gao, J. 2020
Giannopoulou I, 2020*
Giebel C, 2020
Giuseppe, M.D, 2020
Gonzalez-Sanguino, C, 2020*
Guo, Y, 2020
Hamm, M.E, 2020*
Hazarika, M, 2021
He, Q, 2020
11.11 14.0000

Ahmed, M.Z, 2020		28.96 (26.26, 31.77)
Alamri, H.S, 2020		5.45 (4.39, 6.68)
Banna, H.A, 2020	1.1	33.71 (31.26, 36.23)
Barzilay, R, 2020	1.5	22.00 (19.82, 24.31)
Bauerle, A, 2020 Bendau, A, 2020	13.	14.90 (14.35, 15.47) 29.35 (27.44, 31.32)
Cansel, N, 2021	1.7	6.65 (5.85, 7.52)
Cao, W, 2020		24.91 (23.91, 25.93)
Capasso, A, 2021		47.20 (45.91, 48.49)
Casagrande, M, 2020		8.12 (7.03, 9.31)
Cellini, N, 2020	1.1	32.60 (30.06, 35.21)
Cenat, J.M, 2021	1 †	23.44 (21.13, 25.87)
Chen, S, 2020		26.90 (25.92, 27.91)
Cheng, C, 2020		53.33 (49.14, 57.49)
Creese, B, 2020 Dawel, A, 2020		2.44 (1.94, 3.03) 3.78 (2.81, 4.97)
Duncan, G.E, 2020		3.60 (3.04, 4.23)
Duong, K.N.C, 2020		14.08 (12.29, 16.02)
Every-Palmer, S, 2020	2	15.62 (14.06, 17.28)
Fancourt, D, 2021	1.1	22.60 (22.17, 23.03)
Faulker, J, 2020	÷:	1.44 (1.19, 1.71)
Ferrucci, R, 2020		24.50 (23.66, 25.35)
Fisher, J.R.W, 2020	1 🕈 👘	21.00 (20.32, 21.69)
Franceschini, C, 2020	1.	13.15 (12.34, 14.00)
Gao, J. 2020	1	22.60 (21.43, 23.81)
Giannopoulou I, 2020* Giebel C, 2020		7.47 (5.19, 10.33) 11.11 (6.05, 18.25)
Giuseppe, M.D, 2020		51.10 (49.79, 52.41)
Gonzalez-Sanguino, C, 2020*		14.60 (13.44, 15.81)
Guo, Y, 2020	1 ja -	25.40 (23.64, 27.22)
Hamm, M.E, 2020 ^a		82.19 (71.47, 90.16)
Hazarika, M, 2021	1.1-	35.49 (31.45, 39.68)
He, Q, 2020		41.18 (36.14, 46.35)
Hetkamp, M, 2020	•	7.20 (6.81, 7.61)
Huang, Y, 2020	. i •	34.80 (33.36, 36.26)
Hyun, S, 2020		13.11 (10.98, 15.48) 29.55 (26.49, 32.75)
ldrissi, A.J, 2020 Islam, M.S, 2020		29.55 (26.49, 32.75) 37.30 (34.67, 39.98)
Jacob, L, 2020		30.56 (25.41, 36.11)
Jewell, J.S, 2020	1.5	33.98 (31.16, 36.89)
Jiang, W, 2020		32.49 (32.12, 32.87)
Jung, S, 2020*		44.94 (43.29, 46.59)
Kar, N, 2021		15.83 (13.26, 18.67)
Kwong, A.S.F, 2020	14	18.66 (17.25, 20.14)
Lechner, W.V, 2020=	•	9.31 (8.45, 10.22)
Li, S, 2020	P:	4.80 (4.06, 5.62)
Liang, Y. 2020*	Ē:	2.54 (1.39, 4.22)
Lopez-Moreno, M, 2020* Lu. C. 2020	F i	4.73 (2.54, 7.95) 34.40 (31.41, 37.50)
E0, C, 2020	1:-	1.17 (0.24, 3.37)
Lu W 2020a		
Lu, W, 2020* Lu, W-H, 2020	T .	
Lu, W-H, 2020		43.40 (41.20, 45.62)
Lu, W-H, 2020 Makhashvii, N, 2020 Massad, I, 2020 Mazza, C, 2020		43.40 (41.20, 45.62) 23.52 (21.71, 25.39) 12.80 (11.91, 13.73) 6.40 (5.52, 7.38)
Lu, W+1, 2020 Makhashini, N, 2020 Massad, I, 2020 Mazza, C, 2020 Mazza, C, 2020		43.40 (41.20, 45.62) 23.52 (21.71, 25.39) 12.80 (11.91, 13.73) 6.40 (5.52, 7.38) 24.17 (21.79, 26.69)
Lu, W-H, 2020 Makhashvili, N, 2020 Massad, I, 2020 MacZac, C, 2020- MoCrasken, LM, 2020 MoCrasken, LM, 2020-		43.40 (41.20, 45.62) 23.52 (21.71, 25.39) 12.80 (11.91, 13.73) 6.40 (5.52, 7.38) 24.17 (21.79, 26.69) 0.88 (0.38, 1.73)
Lu, VH-2020 Massad, I, 2020 Massad, C, 2020 Massa, C, 2020 Molcay, D, 2020 Molcay, D, 2020		43.40 (41.20, 45.62) 23.52 (21.71, 25.39) 12.80 (11.91, 13.73) 6.40 (5.52, 7.38) 24.17 (21.79, 26.69) 0.88 (0.38, 1.73) 26.50 (25.67, 27.35)
Lu, VH, 2020 Makhashwili, N, 2020 Massad, I, 2020 Maza, C, 2020 McKay, D, 2020 McKay, D, 2020 McKay, D, 2020		43.40 (41.20, 45.62) 23.52 (21.71, 25.39) 12.80 (11.91, 13.73) 6.40 (5.52, 7.38) 24.17 (21.79, 26.69) 0.88 (0.38, 1.73) 26.50 (25.67, 27.35) 50.00 (45.35, 54.45)
Lu, VH-2020 Massard, 1, 2020 Masza, G. 2020 Macza, G. 2020 Molcy, D. 2020 Molcy, D. 2020 Molcy, D. 2020 Molcymania, J. Autocom, A. 2020 Molcymanud, S.M. 2021 Molcymanud, S.M. 2021		43.40 (41.20, 45.82) 23.52 (21.71, 25.39) 23.62 (11.91, 13.73) 64.0 (55.27, 7.38) 24.17 (21.79, 26.69) 0.68 (0.38, 1.73) 26.50 (25.67, 27.36) 50.00 (45.35, 54.65) 47.77 (46.44, 49.28)
Lu, VH, 2020 Makhashwili, N, 2020 Massad, I, 2020 Maza, C, 2020 McKay, D, 2020 McKay, D, 2020 McKay, D, 2020		43.40 (41.20, 45.62) 23.52 (21.71, 25.39) 12.80 (11.91, 13.73) 6.40 (5.52, 7.38) 24.17 (21.79, 26.69) 0.88 (0.38, 1.73) 26.50 (25.67, 27.35) 50.00 (45.35, 54.45)
Lu, VH. 2020 Makhashwili, N, 2020 Masadi, I, 2020 Maza, C, 2020 ^a MoKay, D, 2020 ^b MoKay, D, 2020 ^b Mokay, D, 2020 ^b Mohammadi, S.M, 2021 Mehas, K, 2020		43.40 (41.20, 45.82) 23.52 (21.71, 25.90) 12.80 (11.91, 13.73) 6.40 (55.21, 73.8) 24.17 (21.79, 26.69) 0.88 (0.38, 17.3) 55.01 (25.67, 27.35) 50.00 (45.35, 54.65) 47.77 (46.14, 49.28) 13.33 (17.55, 21.26)
Lu, W+L 2020 Massad, 1, 2020 Massad, 1, 2020 MoCrashen, LM, 2020 MoCrashen, LM, 2020 MoGrambash-Mansourish, A, 2020 Mohammadi, SM, 2021 Mohammadi, SM, 2021 Moham, Y, 2020		43.40 (41.20, 45.62) 23.52 (21.71, 25.59) 12.80 (11.91, 13.73) 64.0 (5.82, 730) 24.17 (21.79, 25.69) 0.88 (0.38, 177) 26.50 (25.67, 27.35) 50.00 (45.35, 54.65) 47.77 (46.14, 42.82) 19.33 (17.55, 21.26) 23.46 (21.76, 26.03)
Lu, VH. 2020 Lu, VH. 2020 Massad, I. 2020 Massad, C. 2020 Macza, C. 2020 Molcario, D. 2020 Molcario, D. 2020 Molcarionad, S. M. 2021 Molcarionad, S. M. 2021 Molcarionad, S. M. 2021 Molcari, N. 2020 Niser, N. 2021 O'Conno, R. C. 2020		43.40 (41.20, 45.82) 23.55 (21.71, 25.39) 12.80 (11.91, 13.73) 6.40 (5.52, 7.38) 24.17 (21.79, 26.66) 0.68 (0.38, 1.73) 50.00 (45.35, 54.65) 47.77 (46.14, 49.20) 19.35 (17.55, 21.26) 23.84 (21.76, 25.03) 14.39 (13.64, 15.17) 18.76 (17.42, 20.21) 7.86 (6.36, 9.11)
Lu, W+L, 2020 Lu, W+L, 2020 Messari, 1, 2020 Messari, 1, 2020 MecSarian, LM, 2020 MecSarian, LM, 2020 MedSarian, LM, 2020 Molamina, K, 2020 Messari, AY, 2020 Naser, AY, 2020 Naser, AY, 2020 Odracobe-Soutalet, P. 2020 Odracobe-Soutalet, P. 2020 Odracobe-Soutalet, P. 2020		41.440 (41.20, 45.62) 21.55 (21.71, 25.39) 12.80 (11.91, 13.73) 64.0 (5.52, 73.8) 24.17 (21.79, 25.69) 05.80 (0.38, 17.73) 26.59 (25.67, 27.35) 50.00 (45.55, 55.65) 40.30 (45.55, 55.65) 41.39 (17.55, 21.26) 23.84 (21.76, 26.03) 41.39 (13.64, 15.17) 18.78 (17.42, 20.21) 7.88 (63.69, 9.11) 10.12 (26.37, 12.0)
Lu, VH-1, 2020 Lu, VH-1, 2020 Massad, I, 2020 Massad, S, 2020- Massad, S, 2020- Moley, D, 2020- Moley, D, 2020- Moley, Massad, SM, 2021 Moley, Lu, 2020 Nasser, AY, 2020 Nasser, AY, 2020 Odirozola-Gonzalez, P, 2020- Odirozola-Gonzalez, P, 2020- Odirozola-Gonzalez, P, 2020-		43.40 (41.20, 45.82) 23.55 (21.71, 25.39) 12.80 (11.91, 13.73) 64.0 (5.52, 7.38) 24.17 (21.79, 26.86) 0.68 (0.38, 1.73) 50.00 (45.35, 54.65) 47.77 (46.14, 42.80) 19.35 (17.55, 21.26) 23.84 (21.76, 26.03) 14.39 (13.64, 15.17) 15.39 (6.36, 9.11) 10.12 (0.37, 12.10) 23.28 (23.73, 33.7)
Lu, W+L 2020 Lu, W+L 2020 Massari, 1, 2020 Massari, 1, 2020 McCratesen, LM, 2020 McCratesen, LM, 2020 McGarbanmadi, S. M, 2021 McGarbanmadi, S. M, 2021 McGarbanmadi, S. M, 2021 McGarbanmadi, S. M, 2021 McGarbanmadi, S. M, 2021 McGarban, C. 2020 Odrozole, C. 2020 Odrozole, S. 2020 Markey, D. 2020		41-340 (41-20, 45-82) 21.55 (21.71, 25-30) 12.80 (11.91, 13.73) 644 (5.52, 738) 24.17 (21.79, 25.69) 05.80 (0.34, 17.73) 26.50 (25.57, 27.35) 50.00 (45.55, 54.55) 47.71 (46.14, 44.28) 19.35 (17.55, 21.26) 23.84 (21.76, 26.33) 14.39 (13.64, 15.17) 15.76 (17.42, 26.21) 7.89 (56.9, 9.11) 10.12 (20.37, 12.10) 28.29 (25.57, 33.37) 5.59 (4.44, 63.3)
Lu, VH-1, 2020 Lu, VH-2, 2020 Massad, 1, 2020 Massad, 5, 2020- Molcay, D, 2020- Molcay, D, 2020- Molcay, D, 2020- Moltay, KJ, 2020 Moltay, KJ, 2020 Massar, AY, 2020 Nassar, AY, 2020 Odricactis-Gonzalez, P, 2020- Odricactis-Gonzalez, P, 2020- Odricactis-Gonzalez, P, 2020- Odricactis-Gonzalez, P, 2020- Odricactis-Gonzalez, P, 2020- Odricactis-Gonzalez, P, 2020- Odricactis-Gonzalez, P, 2020- Dordin, S, 2020- Pandey, D, 2020- Pandey, D, 2020-		43.40 (41.20, 45.82) 23.55 (21.71, 25.39) 12.80 (11.91, 13.73) 64.05 (5.82, 7.83) 24.17 (21.79, 26.59) 0.88 (0.38, 1.73) 50.00 (45.35, 54.65) 47.77 (46.14, 48.28) 10.33 (17.55, 21.26) 23.84 (21.76, 26.03) 14.39 (13.64, 15.17) 14.39 (13.64, 15.17) 15.78 (14.42, 20.21) 7.88 (66.69, 81.1) 10.12 (0.37, 12.10) 24.28 (23.57, 33.37) 5.59 (44.4, 63.53)
Lu, W+L 2020 Lu, W+L 2020 Massari, 1, 2020 Massari, 1, 2020 McCratesen, LM, 2020 McCratesen, LM, 2020 McGarbanmadi, S. M, 2021 McGarbanmadi, S. M, 2021 McGarbanmadi, S. M, 2021 McGarbanmadi, S. M, 2021 McGarbanmadi, S. M, 2021 McGarban, C. 2020 Odrozole, C. 2020 Odrozole, S. 2020 Markey, D. 2020		41-340 (41-20, 45-82) 21.55 (21.71, 25-30) 12.80 (11.91, 13.73) 644 (5.52, 738) 24.17 (21.79, 25.69) 05.80 (0.34, 17.73) 26.50 (25.57, 27.35) 50.00 (45.55, 54.55) 47.71 (46.14, 44.28) 19.35 (17.55, 21.26) 23.84 (21.76, 26.33) 14.39 (13.64, 15.17) 15.76 (17.42, 26.21) 7.89 (56.9, 9.11) 10.12 (20.37, 12.10) 28.29 (25.57, 33.37) 5.59 (4.44, 63.3)
Lu, W+1, 2020 Lu, W+2, 2020 Massari, 1, 2020 Maczar, 0, 2020 McCrateken, LM, 2020 McCrateken, LM, 2020 McGarbaneth-Mansourish, A, 2020 Odracoli, C, 2020 Markey, D, 2020 Pare, M, 2020 Markey, D, 2020 Pare, M, 2020 Markey, D, 2020		41.40, 41.20, 45.62) 23.52 (21.71, 25.39) 12.80 (11.91, 13.73) 54.40 (5.52, 73.8) 24.17 (21.73, 25.69) 02.88 (0.38, 17.73) 25.90 (24.55, 25.45) 50.00 (45.55, 25.45) 23.84 (21.76, 25.63) 23.84 (21.76, 25.63) 23.84 (21.76, 25.63) 23.84 (21.76, 25.63) 23.84 (21.76, 25.63) 23.84 (21.76, 25.63) 23.84 (21.76, 25.63) 23.85 (21.76, 25.73) 23.85 (21.76, 25.75) 23.85 (21.76, 25.75) 23.
Lu, W+L 2020 Lu, W+L 2020 Massard, 1, 2020 Massard, 1, 2020 MacJan, BL, 2020 Molcy, D, 2020 ^a Molcy, D, 2020 ^b Mols, K, 2020 Mols, K, 2020 Massar, AY, 2020 Nassar, AY, 2020 Oxeconor, RC, 2020 Difference, Streppender, Stre		41-40 (41 20, 45.82) 23.52 (21 71, 25.99) 12.80 (11 91, 13.73) 64 (01 55.27.35) 24.17 (21 79, 25.69) 0.88 (0.38, 17.3) 85.00 (25.67, 27.35) 95.00 (45.35, 54.66) 47.77 (46.14, 40.20) 10.33 (17.55, 21.26) 23.54 (21.76, 26.03) 14.39 (13.64, 15.17) 14.39 (13.64, 15.17) 14.73 (17.42, 20.21) 7.88 (68.69, 911) 10.12 (20.37, 12.06) 24.28 (23.57, 33.37) 55.59 (44.4, 653) 15.59 (44.4, 653) 15.59 (44.4, 653) 15.59 (44.4, 653) 15.59 (44.4, 653) 15.59 (44.4, 653) 15.20 (21.38, 33.89) 31.59 (20.75, 34.15) 12.99 (12.21, 13.81)
Lu, W+1, 2020 Lu, W+1, 2020 Massari, 1, 2020 Massari, 1, 2020 McCratesen, LM, 2020 McGranesen, LM, 2020 McGarbanmadi, S. M. 2021 McGarbanmadi, S. 2020 McGarban, C. 2020 Odrozof, S. 2020 Peng, M. 2020 Peng,		41.40, 41.20, 45.62) 23.52 (21.71, 25.39) 12.80 (11.91, 13.73) 40.40 (5.82, 7.38) 24.17 (21.73), 26.69) 0.88 (0.38, 17.73) 26.59 (25.67, 27.35) 50.00 (45.55, 55.65) 47.71 (46.14, 44.23) 10.36 (17.55, 21.28) 23.84 (21.76, 26.63) 14.38 (13.64, 15.17) 14.38 (13.64, 15.17) 15.26 (17.52, 20.21) 7.48 (63.63, 9.11) 10.12 (8.37, 12.10) 23.82 (25.75, 33.37) 5.59 (44.4, 633) 12.89 (10.80, 14.78) 8.15 (60.05, 10.68) 21.59 (13.84, 33.69) 31.59 (21.75, 34.15) 12.99 (12.21, 13.81) 22.47 (20.88, 44.35)
Lu, W+L 2020 Lu, W+L 2020 Massari, L 2020 Massar, L 2020 Mofarin, S. 2020- Mofarin, D. 2020- Mofarination-Hamadu S. 2020- Mofarination, S. 2020- Mofarina, K. 2020 Massar, A. 2020 Massar, A. 2020 Massar, A. 2020 Odrozole-Conzellec, P. 2020- Odrozole-Conzellec, P. 2020- Odrozole-Conzellec, P. 2020- Odrozole, S. 2020- Pandey, D. 2020- Pandey, D. 2020- Pandey, D. 2020- Pandey, D. 2020- Pandey, D. 2020- Pandey, S. 2020- Pandey, D. 2020- Pandey, S. 2		41-40 (41 20, 45.82) 23.52 (21 71, 25.59) 12.80 (11 91, 13.73) 64 (05.82, 738) 24.17 (21 79, 25.69) 0.88 (0.38, 173) 25.00 (45.25, 54.65) 47.77 (46.14, 42.82) 10.33 (17.55, 21.26) 23.54 (21.76, 26.03) 14.39 (13.64, 15.17) 15.79 (17.42, 2021) 7.89 (636, 9.11) 10.12 (20.37, 2021) 7.89 (636, 9.11) 10.28 (10.66, 10.68) 25.59 (44.45, 630) 12.89 (10.66, 10.68) 21.66 (11.38, 33.69) 31.99 (21.75, 34.15) 12.99 (12.21, 13.81) 22.47 (20.88, 24.35) 7.52 (52.31, 04.0)
Lu, W+1, 2020 Lu, W+2, 2020 Massari, 1, 2020 Massari, 1, 2020 McCracken, LM, 2020 McCracken, LM, 2020 McGranewal, SA, 2020 McGarbanewal, McGarbanewal, McGarban		41.340 (41.20, 45.62) 21.55 (21.71, 25.39) 12.80 (11.91, 13.73) 404 (5.52, 738) 24.17 (21.73, 26.69) 02.88 (0.34, 17.73) 26.50 (26.55, 27.35) 50.00 (45.35, 54.65) 47.71 (46.14, 49.28) 19.35 (17.55, 27.26) 21.86 (17.62, 25.26) 21.86 (17.62, 25.26) 21.86 (17.62, 25.26) 21.86 (17.62, 25.27) 15.76 (17.62, 25.27) 12.89 (10.06, 14.78) 15.66 (05.100, 06) 21.06 (11.38, 33.89) 31.59 (26.75, 34.15) 12.99 (12.21, 13.81) 22.47 (20.68, 24.35) 7.52 (52.32, 10.40)
Lu, W+L 2020 Lu, W+L 2020 Massari, L 2020 Massar, L 2020 Massar, C 2020+ Massar, C 2020+ Massar, A 2020- Massar, A 2020 Massar, A 2020 Nassar, A 2020 Nassar, A 2020 Odirozole-Conzalez, P, 2020- Odirozole-Conzalez, P, 2020- Pender, D, 2020- Pender, B, 2020- Robalez, R, 2021 Robalez, R, 2020-		41-40, (41-20, 45-82) 23.55 (21-71, 25-59) (12.80 (11.91, 13.73) 64-0 (5.52, 73.8) 24.17 (21.79, 25.69) 0.89 (0.38, 177) 0.89 (0.38, 177) 0.89 (0.38, 177) 10.35 (17.55, 21.26) 10.36 (17.55, 21.26) 10.36 (17.55, 21.26) 13.36 (17.55, 21.26) 13.36 (17.55, 21.26) 13.36 (17.55, 21.26) 13.36 (17.55, 21.26) 13.36 (13.64, 15.17) 14.39 (13.64, 15.17) 14.39 (13.64, 15.17) 14.39 (13.64, 15.17) 15.26 (3.27, 33.37) 5.59 (4.44, 63) 12.69 (10.20, 11.20) 21.26 (3.17, 13.81) 13.82 (29.75, 34.55) 13.82 (29.75, 54.55) 13.82 (29.75, 54.55)
Lu, W+1, 2020 Lu, W+2, 2020 Massari, 1, 2020 Massari, 1, 2020 McCaracken, LM, 2020 McCaracken, LM, 2020 McGarane, LM, 2020 McGarane, A, 202		41-340 (41-20, 45-62) 21.55 (21.71, 25-39) 12.80 (11.91, 13.73) 404 (5.82, 738) 24.17 (21.73, 25.69) 26.81 (0.34, 17.73) 26.50 (26.55, 27.35) 50.00 (45.35, 54.65) 47.71 (46.14, 49.28) 19.35 (17.85, 21.26) 21.86 (17.16, 25.26) 21.86 (17.16, 25.26) 21.86 (17.16, 25.27) 14.82 (13.64, 54.71) 14.82 (13.64, 54.71) 14.82 (13.64, 54.71) 14.82 (13.64, 54.71) 14.82 (13.64, 54.71) 14.82 (13.64, 54.71) 14.82 (13.64, 54.71) 15.84 (14.65, 17.71) 15.84 (13.63, 54.71) 12.86 (10.27, 13.81) 22.47 (20.88, 24.45) 7.52 (52.33, 10.40) 15.84 (17.04, 22.88) 12.86 (10.70, 42.28) 12.86 (10.70, 42.28) 12.86 (10.70, 42.28)
Lu, W+L 2020 Lu, W-L 2020 Massari, 1, 2020 Massar, 1, 2020 MacSar, 0, 2020- MacSar, 0, 2020- MacSar, 0, 2020- MacSar, 0, 2020- Massar, A, 2020 Massar, A, 2020 Nassar, A, 2020 Odirozole-Gouzalez, P, 2020- Odirozole-Gouzalez, P, 2020- Perg, M, 2020- Perg, M, 2020- Perg, M, 2020- Perg, M, 2020- Rosalez, P, 2020- Rosalez, R, 2020 Stabi, SM, 2020 Stabi, SM, 2020 Stabi, SM, 2020		41-40, (41-20, 45-82) 23.55 (21-71, 25-39) 12.80 ((11-91, 13-73) 404 (55.27, 23.8) 24.17 (21-79, 25.69) 26.50 (25.67, 27.35) 50.00 (45-35, 54.65) 47.77 (46.14, 49.28) 19.33 (17-55, 21.26) 23.84 (21.76, 26.03) 14.39 (13.64, 15.17) 16.78 (17-42, 20.21) 7.89 (636, 9.11) 10.12 (26.37, 20.21) 7.89 (636, 9.11) 10.28 (23.57, 23.37) 55.59 (44.4, 63) 12.80 (10.80, 14.70) 81.58 (26.37, 53.45) 12.80 (10.80, 14.70) 15.28 (17.24, 13.81) 12.24 (10.80, 24.35) 7.25 (53.31, 04.0) 21.26 (0.70, 21.80) 12.80 (10.74, 15.81) 12.80 (10.74, 15.81) 12.80 (10.74, 15.81) 12.80 (10.74, 15.83)
Lu, W+1, 2020 Lu, W+2, 2020 Massari, 1, 2020 Massari, 1, 2020 McCaracken, LM, 2020 McCaracken, LM, 2020 McGarane, LM, 2020 McGarane, A, 202		41-340 (41-20, 45-62) 21.55 (21.71, 25-39) 12.80 (11.91, 13.73) 404 (5.82, 738) 24.17 (21.73, 25.69) 26.81 (0.34, 17.73) 26.50 (26.55, 27.35) 50.00 (45.35, 54.65) 47.71 (46.14, 49.28) 19.35 (17.85, 21.26) 21.86 (17.16, 25.26) 21.86 (17.16, 25.26) 21.86 (17.16, 25.27) 14.82 (13.64, 54.71) 14.82 (13.64, 54.71) 14.82 (13.64, 54.71) 14.82 (13.64, 54.71) 14.82 (13.64, 54.71) 14.82 (13.64, 54.71) 14.82 (13.64, 54.71) 15.84 (14.65, 17.71) 15.84 (13.63, 54.71) 12.86 (10.27, 13.81) 22.47 (20.88, 24.45) 7.52 (52.33, 10.40) 15.84 (17.04, 22.88) 12.86 (10.70, 42.28) 12.86 (10.70, 42.28) 12.86 (10.70, 42.28)
Lu, W+1, 2020 Lu, W+2, 2020 Massari, 1, 2020 Massari, 1, 2020 McCracken, LN, 2020 McCracken, LN, 2020 McGrannesti, SM, 2020 McGrannesti, SM, 2020 McGrannesti, SM, 2020 McKas, K, 2020 Odrozov, FC, 2020 Ddrozov, FC, 2020 McKas, L, 2020 FL, 2020 FL, 2020 McKas, L, 2020 Selfin, S, 2020		41-340 (41-20, 45-62) 21.55 (21, 71, 25-39) 12.80 (11, 91, 13, 73) 42.40 (5.82, 73) 24.47 (21, 73, 26.69) 0.88 (0.34, 17, 73) 24.59 (25.67, 27, 35) 50.00 (45.35, 54.65) 47.71 (46.14, 49.28) 13.53 (17.55, 21.26) 23.84 (21.76, 25.03) 14.39 (13.44, 15.77) 14.39 (13.44, 15.77) 14.39 (13.44, 15.77) 14.39 (13.44, 15.77) 14.39 (13.44, 15.77) 14.39 (13.44, 15.77) 14.39 (13.44, 15.77) 15.89 (43.44, 563) 15.96 (4.44, 563) 15.96 (4.44, 563) 12.89 (10.86, 14.78) 12.89 (10.86, 14.78) 13.96 (4.44, 453) 12.89 (10.86, 14.78) 12.89 (10.86, 14.78) 12.99 (12.21, 13.81) 22.47 (20.86, 24.45) 7.52 (52.3, 10.40) 13.84 (17.54, 24.85) 12.82 (17.04, 22.88) 12.86 (10.27, 15.43) 15.84 (13.67, 15.43) 15.84 (13.67, 15.43) 15.84 (13.67, 15.83) 15.85 (13.67, 15.83) 15.85 (13.67, 15.83) 15.85 (13.67, 15.83) 15.85 (13.67, 15.83) 15.85 (13.67, 15.83) 15.25 (13.67
Lu, W+L 2020 Lu, W+L 2020 Massad, 1, 2020 Massad, 1, 2020 Macaz, 0, 2020- Macaz, 0, 2020- Macaz, 1, 2020- Macaz, 1, 2020- Macaz, 1, 2020- Massad, 1, 2021- Massad, 1, 2021- Massad, 1, 2021- Massad, 1, 2021- Massad, 1, 2021- Massad, 1, 2020- Massad, 2, 2020- Massad, 2		41-40, 41-20, 45-82) 23.55 (21.71, 25.39) 12.80 (11.91, 13.73) 40.40 (5.82, 73.8) 24.17 (21.79, 25.69) 26.81 (0.38, 17.7) 26.50 (26.57, 27.35) 50.00 (45.35, 54.65) 47.71 (46.14, 40.20) 10.33 (17.52, 21.26) 23.84 (21.76, 26.03) 14.39 (13.84, 15.17) 16.78 (17.82, 20.21) 7.88 (636, 9.11) 10.2 (26.37, 20.21) 7.88 (636, 9.11) 10.2 (26.37, 12.10) 28.28 (22.57, 33.37) 55.96 (44.4, 683) 12.89 (10.80, 14.78) 15.69 (6.51 (10.80) 21.05 (11.38, 33.89) 31.59 (20.75, 34.15) 12.92 (10.22, 11.381) 22.47 (20.86, 24.35) 7.52 (5.23, 10.40) 21.28 (20.70, 21.83) 12.89 (10.74, 22.88) 12.89 (10.27, 15.43) 10.89 (17.84, 10.95) 10.23 (17.88, 12.99) 8.69 (7.45, 10.55) 6.27 (5.23, 12.16) 12.72 (20.54, 491)
Lu, W41, 2020 Lu, W42, 2020 Massad, 1, 2020 Massad, 1, 2020 McCatchen, LU, 2020 McCatchen, LU, 2020 McGanabash-Mansourieh, A 2020- McManwadi, Ski, 2020 Molaser, A, 20		41-40, 41-20, 45-82) 21.55, 2(1, 71, 25-39) 12.80, (11, 91, 13, 73) 42.40, (5.82, 73) 24.47, (21, 73, 26.69) 02.80, (0, 30, 17, 73) 24.50, (25.67, 27.35) 50.00, (45.35, 54.65) 47.71, (46, 14, 49.28) 10.35, (17, 55, 27.26) 23.84, (21, 76, 26.03) 14.39, (13, 44, 15, 17) 14.39, (13, 44, 15, 17) 14.39, (13, 44, 15, 17) 14.39, (13, 44, 15, 17) 14.39, (13, 44, 15, 17) 15.59, (44, 46, 63) 12.69, (10, 30, 14.77) 15.69, (44, 66, 63) 21.69, (11, 38, 31.86) 21.69, (11, 21, 13.81) 22.47, (20, 68, 24.85) 7.52, (5.23, 10.40) 15.84, (13, 75, 14.81) 15.84, (13, 75, 14.81) 15.24, (12, 75, 14
Lu, W4. 2020 Lu, W4. 2020 Massad, 1, 2020 Massad, 1, 2020 MacZa, 0, 2020- MacZa, 0, 2020- MacZa, 0, 2020- MacZa, 0, 2020- MacZa, 0, 2020- MacZa, 1, 2020- Mass, 1, 2020 Mass, 1, 2020 Mass, 1, 2020 Odrozol, C, 2020 Parg, M, 2020- Parg, M, 2020- Pardsy, D, 2020- Parg, M, 2020- Pardsy, D, 2020- Parg, M, 2020- Pardsy, D, 2020- Parg, M, 2020- Pardsy, D, 2020- Parg, M, 2020- Sadi, S, 2020- Sadi, S		41-40, 41-20, 45-82) 23.52 (21.71, 25.39) 12.80 (11.91, 13.73) 40.40 (5.82, 73.8) 24.17 (21.73, 25.69) 26.80 (23.81, 737) 26.50 (25.57, 72.5) 50.00 (45.35, 54.65) 41.30 (17.55, 21.26) 23.84 (21.76, 26.03) 41.30 (17.56, 21.26) 23.84 (21.76, 26.03) 41.30 (13.64, 15.17) 13.78 (16.80, 91.11) 10.72 (8.37, 12.10) 24.28 (23.57, 33.37) 55.59 (44.4, 683) 12.80 (10.80, 14.78) 81.56 (60.5, 10.68) 21.65 (11.38, 33.68) 31.59 (24.75, 33.415) 12.80 (10.27, 15.43) 12.80 (10.27, 15.43) 12.80 (10.27, 15.43) 12.80 (10.27, 15.43) 10.23 (17.64, 22.88) 12.86 (17.47, 10.55) 82.77 (23.24, 12.10) 23.72 (25.67, 30.55) 82.77 (32.24, 21.10) 23.72 (25.67, 30.55) 82.77 (32.24, 21.10) 23.72 (25.67, 30.57) 53.77 (32.24, 57.30) 55.77 (32.34, 57.30) 55.77 (32
Lu, W-H. 2020 Massard, 1, 2020 Massard, 1, 2020 Macza, C. 2020- MoCaradien, L. 2020 MoCaradien, L. 2020 MoCaradien, L. 2020 MoSar, D. 2020- Motal, S. 2020- Motal, S. 2020 Massar, A. Y. 2020 Nassar, A. Y. 2020 Odecord, C. C. 2020 Odecord, C. C. 2020 Odecord, C. C. 2020 Odecord, C. 2020 Pandey, J. 2020 Pa		41-40, 41-20, 45-82) 21.55, 2(1, 71, 25-39) 12.80, (11, 91, 13, 73) 42.40, (5.82, 73) 24.47, (21, 73, 26.69) 02.80, (0, 84, 17, 73) 24.50, (25, 67, 27, 35) 50.00, (45, 35, 456) 47.71, (46, 14, 49, 28) 10.35, (17, 55, 27, 28) 21.84, (17, 42, 20, 21) 7.89, (5.80, 51, 15) 11.87, (17, 42, 20, 21) 7.89, (5.80, 51, 16) 12.80, (10, 20, 71, 27) 12.80, (10, 30, 71, 27) 12.80, (11, 30, 31, 38) 21.80, (11, 33, 31, 38)) 21.80, (11, 34, 38)) 21.80, (11, 34, 38)) 21.80, (11, 34, 38)) 21.80, (11, 34, 38))
Lu, W-H. 2020 Lu, W-H. 2020 Massari, 1, 2020 Massar, 1, 2020 McCaraten, L.M. 2020 McCaraten, L.M. 2020 McKay, D. 2020- McMas, K. 2020 Massar, A.Y. 2020 Massar, A.Y. 2020 Massar, A.Y. 2020 Odrozole, C., 2020 Odrozole, C., 2020 Odrozole, D. 2020 Para, M. 2020- Para, M. 2020- Sala, S. 2020 Shar, L. R. 2020 Shar, M. R. 2020 Shar, M. 2020- Shar, M.		41-40, 41-20, 45-82) 21.55 (21.71, 25.39) 12.80 (11.91, 13.73) 64-0 (5.82, 73.8) 24.17 (21.73, 25.69) 24.17 (21.73, 25.69) 26.80 (23.81, 73.7) 26.50 (26.55, 73.25) 50.00 (45.55, 54.55) 47.71 (46.14, 49.28) 19.33 (17.55, 21.28) 23.84 (21.76, 26.03) 41.39 (13.64, 15.17) 10.32 (17.52, 22.02) 7.88 (56.85, 9.11) 10.12 (23.77, 22.02) 7.89 (56.95, 11.00) 22.89 (24.47, 52.02) 7.89 (56.95, 11.00) 22.89 (24.47, 52.02) 7.89 (56.95, 11.00) 22.80 (23.77, 33.37) 55.96 (44.4, 68.3) 12.89 (10.80, 14.78) 81.56 (60.5, 10.68) 21.06 (11.38, 33.89) 31.59 (29.77, 54.31) 12.90 (10.27, 15.81) 10.21 (7.64, 71.93) 10.22 (7.20, 44.91) 12.87 (10.57, 19.33) 10.23 (7.86, 12.09) 8.69 (7.45, 10.55) 8.27 (22.6, 44.91) 22.47 (20.86, 75.83, 10.55) 15.90 (21.75, 87.86) 15.90 (21.75, 87.86) 15.90 (21.75, 87.86) 15.90 (21.75, 87.86) 15.90 (21.75, 87.86) 15.90 (21.75, 87.86) 15.90 (21.20, 17.29) 15.90 (21.20
Lu, W-H. 2020 Massard, 1, 2020 Massard, 1, 2020 Macza, C. 2020- Motisar, D. 2020- Motisar, D. 2020- Motisar, D. 2020- Motisar, K. 2020 Motisar, K. 2020 Motisar, K. 2020 Massar, A. 2020 Massar, A. 2020 Massar, A. 2020 Odeconor, R. C. 2020 Odeconor, C. 2020 Massar, M. 2020- Pandey, D. 2020- Stabilis, R. M. 2020- Stabilis, R. 2020- Stabilis, S. 2020- Stab		41-40, 41-20, 45-82) 21.55, 2(1, 71, 25-39) 12.80, (11, 91, 13, 73) 42.40, (5.82, 73) 24.47, (21, 73, 26.69) 02.80, (0, 84, 17, 73) 24.50, (25.67, 27.35) 50.00, (45.35, 54.65) 47.71, (46.14, 49.28) 10.35, (17, 55, 27.26) 23.84, (21, 76, 26.03) 14.39, (13, 44, 15, 17) 14.39, (13, 44, 15, 17) 14.39, (13, 44, 15, 17) 14.39, (13, 44, 15, 17) 14.39, (13, 44, 15, 17) 15.59, (44, 46, 63) 12.69, (10, 30, 14.77) 15.69, (44, 66.83) 21.69, (11, 33, 31.89) 21.69, (11, 23, 31.89) 21.69, (11, 23, 31.89) 21.69, (11, 23, 31.89) 21.69, (11, 24, 21.81) 12.69, (10, 27, 15.41) 15.89, (15, 33, 16.31) 15.87, (15, 33, 30) 22.77, (25, 25, 30.63) 15.73, (25, 55, 30.60) 15.73, (25, 65, 37.81) 15.30, (12, 20, (17, 20) 15.30, (12, 30, 16.70) 15.30, (12, 30, 16.70)
Lu, W-H. 2020 Massari, 1, 2020 Massari, 1, 2020 Massari, 1, 2020 Motion, 0, 2020- Motion, 0, 2020- Motion, 0, 2020- Motion, 0, 2020- Motion, 0, 2020 Motion, 0, 2020 Motion, 0, 2020 Motion, 0, 2020 Motion, 0, 2020 Odircond-Gonzalez, P, 2020- Odircond-Gonzalez, P, 2020- Parto, C, 2020- Parto, N, 2020- Parto, S, 2020- Parto, S, 2020- Parto, S, 2020- Stabi, S, 2020- Stabi, S, Au, 2020- Stabi		41-40, 41-20, 45-82) 21.55 (21.71, 25.39) 12.80 (11.91, 13.73) 64-0 (5.82, 73.8) 24.17 (21.73, 25.69) 24.17 (21.73, 25.69) 26.80 (23.81, 73.7) 26.50 (26.55, 73.25) 50.00 (45.55, 54.55) 47.71 (46.14, 49.28) 19.33 (17.55, 21.28) 23.84 (21.76, 26.03) 41.39 (13.64, 15.17) 10.32 (17.52, 22.02) 7.88 (56.85, 9.11) 10.12 (23.77, 22.02) 7.89 (56.95, 11.00) 22.89 (24.47, 52.02) 7.89 (56.95, 11.00) 22.89 (24.47, 52.02) 7.89 (56.95, 11.00) 22.80 (23.77, 33.37) 55.96 (44.4, 68.3) 12.89 (10.80, 14.78) 81.56 (60.5, 10.68) 21.06 (11.38, 33.89) 31.59 (29.77, 54.31) 12.90 (10.27, 15.81) 10.21 (7.64, 71.93) 10.22 (7.20, 44.91) 12.87 (10.57, 19.33) 10.23 (7.86, 12.09) 8.69 (7.45, 10.55) 8.27 (22.6, 44.91) 22.47 (20.86, 75.83, 10.55) 15.90 (21.75, 87.86) 15.90 (21.75, 87.86) 15.90 (21.75, 87.86) 15.90 (21.75, 87.86) 15.90 (21.75, 87.86) 15.90 (21.75, 87.86) 15.90 (21.20, 17.29) 15.90 (21.20
Lu, W4. 2020 Lu, W4. 2020 Massari, 1, 2020 Massari, 1, 2020 McGranbarth, Marsourish, A. 2020- McGranbarth, Marsourish, A. 2020- Mohammadi, S.M. 2021 Moham, K., 2020 Naser, A. Y. 2020 Naser, A. Y. 2020 Odirozofe-Jonzialez, P. 2020- Odirozofe-Jonzialez, P. 2020- Damis, O. A. 2020- Paus, M. 2020- Paus, M. 2020- Paus, L. 2020- Paus, L. 2020- Sadit, S. 2020-		41-40, 41-20, 45-82) 21.55 (21.71, 25.39) 12.80 (11.91, 13.73) 540 (5.82, 73.8) 24.17 (21.73), 25.69) 24.57 (21.73), 25.69) 26.50 (24.55, 55.455) 50.00 (45.55, 55.455) 50.00 (45.55, 55.455) 19.32 (17.82, 26.30) 19.32 (17.82, 26.30) 19.32 (17.82, 26.30) 19.32 (17.82, 26.20) 19.32 (17.82, 26.20) 19.32 (17.84, 26.30) 19.32 (17.84, 26.20) 19.32 (17.84, 27.20) 12.89 (10.80, 14.78) 8.15 (60.56, 10.86) 21.56 (11.38, 33.89) 31.59 (20.75, 34.15) 12.89 (10.87, 19.83) 12.89 (10.87, 15.83) 15.89 (12.87, 15.83) 15.89 (12.87, 15.83) 15.89 (12.87, 15.83) 15.97 (12.65, 63.78) 15.97 (12.65, 63.78) 15.97 (12.65, 63.78) 15.97 (12.65, 63.78) 15.97 (12.65, 63.78) 15.97 (12.65, 63.78) 15.90 (12.75, 13.21) 15.99 (12.75, 13.21) 15.99 (12.75, 13.21) 15.99 (12.75, 13.21) 15.99 (12.75, 13.71) 15.99 (12.75, 13.71) 15.99 (12.75, 13.71) 15.90 (12.75, 13.71)
Lu, V4.1.2020 Massai, 1, 2020 Massai, 1, 2020 Macia, 0, 2020- Molian, D, 2020- Molan, D, 2020- Molan, N, 2020 Molan, N, 2020 Molan, N, 2020 Massi, A, 2020 Massi, A, 2020 Odirozole-Conzelec, P, 2020- Odirozole-Conzelec, P, 2020- Perg, M, 2020- Perg, M, 2020- Perg, M, 2020- Perg, M, 2020- Stab, S, MA, 2020- S		41-40, 41-20, 45-82) 21.55, 2(1, 71, 25-39) 12.80, (11, 91, 13, 73) 42.40, (5.82, 73) 24.47, (21, 73, 26.69) 02.80, (0, 84, 17, 73) 24.50, (25.67, 27.35) 50.00, (45.35, 54.65) 47.71, (46, 14, 49.28) 13.93, (17, 85, 27.26) 23.84, (21, 76, 26.03) 14.39, (13, 44, 15, 17) 14.39, (13, 44, 15, 17) 15.59, (44, 66.03) 12.69, (10, 73, 12.03) 21.69, (11, 23, 31.89) 21.69, (11, 24, 31.81) 12.69, (12, 71, 54.31) 15.89, (15, 30, 16.30) 15.73, (12, 65, 30.60) 15.73, (12, 65, 30.60) 15.74, (12,
Lu, V4.1 2020 Lu, V4.2 2020 Massari, 1, 2020 Massari, 1, 2020 Maczar, 0, 2020- MacZar, 0, 2020- MacZar, 0, 2020- MacZar, 0, 2020- MacZar, 0, 2020- MacZar, 0, 2020 Massari, N, 2020 Massari, N, 2020 Massari, N, 2020 Odicacio-Canzalez, P. 2020- Odicacio-Canzalez, P. 2020- Marsari, N, 2020- Pauci, M. 2020- Sadit, F. 2020- Sadit, S. 2020 Sadit, F. 2020- Sadit, S. 2020- Sad		41-40, 41-20, 45-82) 21.55 (21.71, 25.39) 12.80 (11.91, 13.73) 544 (5.52, 73.8) 24.17 (21.73), 25.69) 24.17 (21.73), 25.69) 26.8 (0.34, 17.37) 25.50 (24.55, 55.455) 50.00 (45.55, 52.128) 23.84 (21.76, 26.03) 19.36 (17.85, 21.28) 23.84 (21.76, 26.03) 19.36 (17.85, 22.28) 23.84 (21.76, 26.03) 19.36 (17.85, 22.28) 23.84 (21.76, 26.03) 19.36 (17.85, 22.28) 19.36 (17.85, 22.28) 19.36 (17.85, 22.28) 19.36 (17.85, 23.28) 19.36 (17.85, 23.28) 19.36 (17.85, 23.28) 19.36 (17.85, 23.28) 19.36 (17.85, 23.28) 19.36 (17.85, 23.28) 19.36 (17.95, 23.45) 19.36 (17.95, 23.45) 19.36 (17.94, 22.88) 19.36 (17.94, 22.88) 19.37 (12.05, 63.78) 19.36 (17.94, 22.88) 19.37 (12.05, 63.78) 19.36 (17.94, 22.88) 19.37 (12.05, 63.78) 19.30 (17.31, 19.31) 19.36 (17.94, 21.96) 25.77 (12.05, 63.78) 19.30 (17.31, 19.51) 19.30 (17.31, 19.51) 19
Lu, V4.1.2020 Lu, V4.2.2021 Massari, 1, 2020 Massar, 1, 2020 Mackar, D, 2020- Mackar, D, 2020- Molammadi, S.M. 2021 Molammadi, S.M. 2021 Molammadi, S.M. 2021 Molammadi, S.M. 2021 Molammadi, S.M. 2021 O'Connor, R.C. 2020 O'dorcoll-Concalet, P. 2020- O'doraci, C. 2020 O'dorcoll-Concalet, P. 2020- O'doraci, C. 2020 O'doraci, C. 2020 O'doraci, C. 2020 O'doraci, C. 2020 Perg, M. 2020- Perg, M. 2020- Stah, S. M. 2020- Tumello, C. 2020 Varman, P. 2020 Varman, P. 2020 Varman, C. 2020 (b)- Warn, M. 2020- Varman, M.		41-40, 41-20, 45-82) 23.55 (21.71, 25.39) 12.80 (11.91, 13.73) 24.17 (21.79, 25.69) 24.17 (21.79, 25.69) 26.10 (25.57, 27.35) 25.00 (25.57, 27.35) 25.00 (25.57, 27.35) 25.00 (25.57, 27.35) 25.00 (25.35, 24.65) 41.30 (13.64, 15.71) 10.33 (17.52, 21.26) 23.84 (21.76, 26.03) 14.30 (13.64, 15.71) 10.72 (0.71, 24.02) 23.84 (21.76, 22.02)1 7.89 (636, 9.11) 10.24 (0.71, 24.02) 25.95 (4.44, 63) 12.80 (10.80, 14.70) 24.28 (23.57, 33.37) 55.95 (4.44, 63) 12.80 (10.80, 14.70) 24.28 (23.57, 33.37) 55.95 (4.44, 63) 12.80 (10.80, 14.70) 24.28 (20.57, 33.37) 55.95 (4.44, 63) 12.80 (10.80, 14.70) 24.29 (12.21, 13.81) 12.84 (17.04, 22.88) 12.80 (10.27, 15.43) 10.23 (17.63, 12.90) 8.80 (7.45, 10.05) 8.27 (26.24, 10.51) 15.90 (15.20, 16.70) 15.90 (15.20, 16.70) 15.80 (15.70, 12.61) 15.80 (15.70, 12.61) 15.90 (14.20, 17.20) 24.70 (26.22, 23.140) 24.70 (26.75, 35.67) 15.70 (14.25, 16.65) 24.70 (26.75, 35.67) 15.70 (14.25, 16.65) 25
Lu, V4.1 2020 Lu, V4.2 2020 Massari, 1, 2020 Massari, 1, 2020 Maczar, C. 2020- MacGartane, L.M. 2020 MacGartane, L.M. 2020 Massar, K.Y. 2020 Massar, K.Y. 2020 Massar, K.Y. 2020 Massar, K.Y. 2020 Odracos, C. 2020 Datasar, L. 2020 Paus, C. 2020 Paus, C. 2020 Paus, C. 2020 Paus, C. 2020 Paus, C. 2020 Paus, C. 2020 Paus, L. 2020 Sadis, S. 2020		41-40, 41-20, 45-82) 21-56, 2(17, 12, 25-30) 12-80, (11, 91, 13, 73) 24-64 (5.82, 73) 24-17 (21, 73), 25-66) 24-17 (21, 73), 25-66) 25-67, 27-35) 50-00, 45-55, 55-55 10-36, 47-75, 46-54, 44-920) 10-36, 17, 85, 45-55 10-36, 47-75, 47-64, 54, 49-20) 10-36, 17, 85, 42-57 10-36, 47-85, 47-57 10-36, 47-85, 47-57 10-36, 47-45, 47-20 10-36, 97-15, 12-00 22-36, 22-37, 23-20, 12-00 22-36, 22-37, 23-20, 12-00 22-36, 22-37, 23-20, 12-00 22-36, 22-37, 23-20, 12-00 22-36, 22-37, 23-37, 15-00 22-36, 22-37, 23-37, 15-00 22-36, 22-37, 22-37, 23-37, 15-00 21-36, 11-38, 33-389) 31-26, 47-04, 47-30 21-36, 47-10, 42-289, 12-26, 43-50 7-52, (52-36, 14-30) 10-56, 71, 45-20, 41-30 22-77, (22-65, 58-76) 15-30, 16-70, 12-280 12-30, 77-36, 12-200 15-57, 142-56, 13-70 22-77, 12-55, 30-200 15-57, 142-56, 13-70 23-70, 22-57, 13-70
Lu, V4.1.2020 Lu, V4.2.2021 Massari, 1, 2020 Massar, 1, 2020 Mackar, D, 2020- Mackar, D, 2020- Molammadi, S.M. 2021 Molammadi, S.M. 2021 Molammadi, S.M. 2021 Molammadi, S.M. 2021 Molammadi, S.M. 2021 O'Connor, R.C. 2020 O'dorcoll-Concalet, P. 2020- O'doraci, C. 2020 O'dorcoll-Concalet, P. 2020- O'doraci, C. 2020 O'doraci, C. 2020 O'doraci, C. 2020 O'doraci, C. 2020 Perg, M. 2020- Perg, M. 2020- Stah, S. M. 2020- Tumello, C. 2020 Varman, P. 2020 Varman, P. 2020 Varman, C. 2020 (b)- Warn, M. 2020- Varman, M.		41-40, 41-20, 45-82) 23.52 (21.71, 25.39) 12.80 (11.91, 13.73) 54.40 (5.52, 73.8) 24.17 (21.79, 25.69) 26.81 (0.38, 17.7) 26.50 (26.57, 27.35) 50.00 (26.57, 27.35) 50.00 (26.57, 27.35) 50.00 (26.57, 27.35) 50.00 (26.57, 27.35) 10.33 (17.52, 21.26) 21.34 (21.76, 26.03) 14.39 (13.64, 15.17) 16.78 (17.42, 20.21) 7.89 (636, 9.11) 10.2 (26.37, 20.21) 7.89 (26.57, 20.21) 7.89 (26.57, 20.21) 7.89 (26.57, 33.77) 55.59 (4.44, 68.3) 12.89 (10.80, 14.78) 12.69 (11.94, 12.84) 12.69 (12.76, 15.43) 10.23 (17.31, 15.91) 10.23 (17.31, 15.91) 15.59 (16.57, 16.37) 15.69 (16.50, 16.77) 15.69 (16.57, 15.77) 15.69 (16.57, 15.77) 15.69 (16.57, 15.77) 15.69 (16.57, 15.77) 15.69 (16.57, 15.77) 15.69 (16.57, 15.77) 15.69 (16.57, 15.77) 15.67 (12.86, 15.77) 15.67 (12.86, 15.77) 15.67 (12.86, 15.77) 15.67 (14.26, 15.77) 15.77 (14.27, 15.97) 15.77 (14.27, 15.97) 15.77 (14.27, 15.97) 15.77 (14.27, 15.97) 15.77 (14.27, 15.97) 15.77 (14.27,
Lu, V4.1 2020 Lu, V4.2 2020 Massari, 1, 2020 Massari, 1, 2020 Maczar, 0, 2020- MacSarian, LM, 2020 MacSarian, LM, 2020 Massar, X, 2020 Massar, X, 2020 Massar, X, 2020 Massar, X, 2020 Odiracio-Courtalec, P, 2020 Paus, M, 2020 Paus, L, 2020 Paus, L, 2020 Sadit, S, 2020 Sadit,		41-40, 41-20, 45-82) 21-26, 2(17, 12, 25-39) 12-26, (11, 12, 13, 13) 24-17 (21, 17), 25-69) 24-17 (21, 17), 25-69) 24-17 (21, 17), 25-69) 26-8 (0, 23, 17, 37) 26-90 (24, 55, 55, 55) 21-26, 17, 25, 54-55) 21-26, 17, 25, 54-55) 21-26, 17, 25, 22-20) 21-26, 17, 25, 22-20, 22-2
Lu, V4.1.2020 Lu, V4.2.2021 Massari, 1.2020 Massar, 1.2020 Mackar, D. 2020- Mackar, D. 2020- Mackar, D. 2020- Martanai, S.M. 2021 Martanai, S.M. 2021 Massar, A. 2020 Nassar, A. 2020 Odir.2026-Gaucalez, P. 2020- Odir.2026-Gaucalez, P. 2020- Paradar, D. 2020- Paradar, D. 2020- Paradar, D. 2020- Paradar, D. 2020- Rabard, R. 2021 Rabard, S. 2020- Rabard, R. 2021 Rabard, S. 2020- Stah, S. M. 2020- Stah, S. Stah, S.		41-40, 41-20, 45-82) 23.52 (21.71, 25.39) 12.80 (11.91, 13.73) 54.40 (5.52, 73.8) 24.17 (21.79, 25.69) 26.81 (0.38, 17.7) 26.50 (26.57, 27.35) 50.00 (26.57, 27.35) 50.00 (26.57, 27.35) 50.00 (26.57, 27.35) 50.00 (26.57, 27.35) 10.33 (17.52, 21.26) 21.34 (21.76, 26.03) 14.39 (13.64, 15.17) 16.78 (17.42, 20.21) 7.89 (636, 9.11) 10.2 (26.37, 20.21) 7.89 (636, 9.11) 10.2 (26.37, 20.21) 7.89 (26.57, 20.21) 7.89 (26.57, 33.77) 55.59 (4.44, 68.3) 12.89 (10.80, 14.78) 12.69 (10.77, 15.43) 10.23 (17.31, 15.91) 10.23 (17.63, 12.69) 15.69 (12.80, 17.39) 15.69 (12.80, 17.39) 15.67 (12.80, 17.3
Lu, V4.1. 2020 Massai, 1, 2020 Massai, 1, 2020 Mackar, D, 2020- Mackar, D, 2020- Mackar, L. M, 2020 Mackar, L. M, 2020 Massai, A, 2020 Massai, A, 2020 Massai, A, 2020 Massai, A, 2020 Odiscube. Gaussaier, P. 2020- Odiscube. Gaussaier, P. 2020- Paus, M. 2020- Paus, M. 2020- Paus, M. 2020- Paus, M. 2020- Paus, M. 2020- Paus, M. 2020- Saink, S. 2020- S		41-440 (41 20, 44.52) 42.53 (21 71, 25.39) 12.80 (11 91, 13.73) 404 (55.2, 73.8) 24.17 (21 73, 25.69) 24.17 (21 73, 25.69) 26.8 (0.38, 173) 26.50 (26.57, 72.5) 50.00 (45.35, 54.65) 41.39 (17.8, 24.63) 13.33 (17.52, 21.26) 23.24 (21.78, 26.03) 14.39 (13.84, 15.17) 10.78 (13.83, 13.91) 21.55 (14.44, 63.02) 12.89 (14.74, 12.10) 22.82 (23.7, 33.37) 55.98 (44.4, 63.02) 21.65 (11.38, 13.89) 31.69 (11.38, 13.89) 31.69 (11.74, 12.88) 12.89 (10.75, 10.80) 21.26 (10.07, 11.83) 12.89 (10.75, 10.81) 10.20 (17.88, 12.09) 8.89 (74.57, 10.55) 15.79 (12.26, 74.37) 15.90 (12.50, 17.29) 15.90 (12.50, 17.29) 15.90 (12.50, 17.29) 15.90 (12.50, 17.29) 15.97 (12.26, 17.29) 15.97 (12.27, 15.49) 15.97 (12.27, 15.49) 15.97 (12.26, 17.29) 15.97 (12.26, 17.29) 15.97 (12.26, 17.29) 15.97 (12.26, 17.29) 15.97 (12.26, 17.29) 15.97 (12.27, 15.49) 15.97 (12.27, 15.49) 15.97 (12.26, 17.29) 15.97 (12.27, 15.49) 15.97 (12.26, 17.29) 15.97 (12.27, 15.49) 15.97 (12.27
Lu, V4.4. 2020 Mussai, 1, 2020 Mussai, 1, 2020 Muscar, C. 2020 Muscar, C. 2020 Mussai, K. 2020 Mussai, M. 2020 Mussai, M. 2020 Mussai, M. 2020 Mussai, M. 2020 Mussai, J. 2020 Mussai,		41-40, 41-20, 45-82) 21-26, 2(17, 12, 25-39) 12-20, (11, 91, 13, 73) 404 (5.82, 73) 24-17 (21, 73), 25-69) 264 (5.82, 73) 25.90 (45.35, 25.45) 47.71 (46.14, 49.23) 13-53 (17.85, 21.26) 21.86 (17.6, 25.26) 21.86 (17.6, 25.26) 21.86 (17.6, 25.26) 21.86 (17.6, 25.27) 21.86 (17.6, 25.27) 21.86 (17.6, 25.27) 21.86 (17.6, 27.27) 22.87 (23.27, 23.37) 55.96 (4.44, 6.83) 12.89 (10.80, 14.73) 85.96 (4.44, 6.83) 12.89 (10.80, 14.73) 85.96 (4.45, 6.83) 12.89 (10.80, 14.73) 85.96 (4.45, 6.83) 12.89 (10.80, 14.73) 85.96 (4.47, 6.83) 12.89 (10.80, 14.73) 85.96 (4.47, 6.83) 12.89 (10.74, 22.83) 12.89 (10.74, 22.83) 12.89 (10.74, 22.83) 12.89 (10.74, 22.83) 12.89 (10.74, 12.83) 10.59 (11.59, 15.30) 10.59 (11.59, 15.30) 10.59 (11.59, 15.30) 10.59 (11.59, 15.30) 15.79 (12.62, 55.78) 15.59 (15.30, 01.72) 15.59 (15.30, 01.72) 15.57 (14.35, 16.85) 12.18 (10.77, 15.91) 15.59 (15.30, 01.72) 15.57 (14.35, 16.85) 12.18 (10.74, 12.67) 15.57 (14.35, 16.85) 12.18 (10.74, 12.67) 15.57 (14.35, 16.85) 12.18 (10.74, 12.67) 15.57 (14.35, 16.85) 12.18 (10.74, 12.67) 15.57 (14.35, 16.85) 12.18 (10.77, 17.90) 25.9 (15.30, 24.77) 25.9 (15.30, 24
Lu, V4-1. 2020 Massai, 1, 2020 Massai, 1, 2020 Massai, 1, 2020- Macrae, C, 2020- Macrae, D, 2020- Massai, 1, 2020 Massai, 2, 2020- Massai, 2, 2020- Martine, M, 2020- Martine, L, 2020- Martine, L, 2020- Martine, X, 2020 Naser, A, 7, 2020 Naser, A, 2020- Orderacide-Gouralies, P. 2020- Orderacide-Gouralies, P. 2020- Orderacide-Gouralies, P. 2020- Orderacide-Gouralies, P. 2020- Pared, M, 2020- Stahl, S. M, 2020- Stahl, S. M, 2020- Stahl, S. M, 2020- Stahl, S. M, 2020- Yaman, P. 2020 Waman, C, 2020 (b)- Waman, C. 2		41-40, 41-20, 45-82) 21-52, (21, 71, 25-39) 12-80, (11, 91, 13, 73) 40-40 (5.82, 73, 73) 24-17 (21, 73, 25-69) 24-17 (21, 73, 25-69) 26-80, 20, 41-73) 26-50 (25-7, 72, 5) 50.00, 145.55, 54-65) 41-39, (17, 82, 41-63) 19-33, (17, 82, 41-63) 19-33, (17, 82, 41-63) 19-34, (17, 82, 42-63) 14-39, (13, 84, 15-17) 10-24, 63, 71, 42-00, 12-00 21-26, 21, 71, 40-10 21-26, 21, 71, 40-10 21-20, 11-27, 15-20 21-20, 11-20, 12-20 21-20, 12-20, 12-20
Lu, V4.4. 2020 Mussai, 1, 2020 Mussai, 1, 2020 Muscar, C. 2020 Muscar, C. 2020 Mussai, K. 2020 Mussai, M. 2020 Mussai, M. 2020 Mussai, M. 2020 Mussai, M. 2020 Mussai, J. 2020 Mussai,		41-40, 41-20, 45-82) 21-26, 2(17, 12, 25-39) 12-20, (11, 91, 13, 73) 404 (5.82, 73) 24-17 (21, 73), 25-69) 264 (5.82, 73) 25.90 (45.35, 25.45) 47.71 (46.14, 49.23) 13-53 (17.85, 21.26) 21.86 (17.6, 25.26) 21.86 (17.6, 25.26) 21.86 (17.6, 25.26) 21.86 (17.6, 25.27) 21.86 (17.6, 25.27) 21.86 (17.6, 25.27) 21.86 (17.6, 27.27) 22.87 (23.27, 23.37) 55.96 (4.44, 6.83) 12.89 (10.80, 14.73) 85.96 (4.44, 6.83) 12.89 (10.80, 14.73) 85.96 (4.45, 6.83) 12.89 (10.80, 14.73) 85.96 (4.45, 6.83) 12.89 (10.80, 14.73) 85.96 (4.47, 6.83) 12.89 (10.80, 14.73) 85.96 (4.47, 6.83) 12.89 (10.74, 22.83) 12.89 (10.74, 22.83) 12.89 (10.74, 22.83) 12.89 (10.74, 22.83) 12.89 (10.74, 12.83) 10.59 (11.59, 15.30) 10.59 (11.59, 15.30) 10.59 (11.59, 15.30) 10.59 (11.59, 15.30) 15.79 (12.62, 55.78) 15.59 (15.30, 01.72) 15.59 (15.30, 01.72) 15.57 (14.35, 16.85) 12.18 (10.77, 15.91) 15.59 (15.30, 01.72) 15.57 (14.35, 16.85) 12.18 (10.74, 12.67) 15.57 (14.35, 16.85) 12.18 (10.74, 12.67) 15.57 (14.35, 16.85) 12.18 (10.74, 12.67) 15.57 (14.35, 16.85) 12.18 (10.74, 12.67) 15.57 (14.35, 16.85) 12.18 (10.77, 17.90) 25.9 (15.30, 24.77) 25.9 (15.30, 24
Lu, V4-1. 2020 Massai, 1, 2020 Massai, 1, 2020 Massai, 1, 2020- Macrae, C, 2020- Macrae, D, 2020- Massai, 1, 2020 Massai, 2, 2020- Massai, 2, 2020- Martine, M, 2020- Martine, L, 2020- Martine, L, 2020- Martine, X, 2020 Naser, A, 7, 2020 Naser, A, 2020- Orderacide-Gouralies, P. 2020- Orderacide-Gouralies, P. 2020- Orderacide-Gouralies, P. 2020- Orderacide-Gouralies, P. 2020- Pared, M, 2020- Stahl, S. M, 2020- Stahl, S. M, 2020- Stahl, S. M, 2020- Stahl, S. M, 2020- Yaman, P. 2020 Waman, C, 2020 (b)- Waman, C. 2		41-40, 41-20, 45-82) 21-52, (21, 71, 25-39) 12-80, (11, 91, 13, 73) 40-40 (5.82, 73, 73) 24-17 (21, 73, 25-69) 24-17 (21, 73, 25-69) 26-80, 20, 41-73) 26-50 (25-7, 72, 5) 50.00, 145.55, 54-65) 41-39, (17, 82, 41-63) 19-33, (17, 82, 41-63) 19-33, (17, 82, 41-63) 19-34, (17, 82, 42-63) 14-39, (13, 84, 15-17) 10-24, 63, 71, 42-00, 12-00 21-26, 21, 71, 40-10 21-26, 21, 71, 40-10 21-20, 11-27, 15-20 21-20, 11-20, 12-20 21-20, 12-20, 12-20
Lu, V4-1. 2020 Massai, 1, 2020 Massai, 1, 2020 Massai, 1, 2020- Macrae, C, 2020- Macrae, D, 2020- Massai, 1, 2020 Massai, 2, 2020- Massai, 2, 2020- Martine, M, 2020- Martine, L, 2020- Martine, L, 2020- Martine, X, 2020 Naser, A, 7, 2020 Naser, A, 2020- Orderacide-Gouralies, P. 2020- Orderacide-Gouralies, P. 2020- Orderacide-Gouralies, P. 2020- Orderacide-Gouralies, P. 2020- Pared, M, 2020- Stahl, S. M, 2020- Stahl, S. M, 2020- Stahl, S. M, 2020- Stahl, S. M, 2020- Yaman, P. 2020 Waman, C, 2020 (b)- Waman, C. 2		41-40, 41-20, 45-82) 23.52 (21.71, 25-39) 12.80 (11.91, 13.73) 404 (5.82, 738) 24.17 (21.73, 26.69) 0.88 (0.34, 17.73) 25.50 (25.67, 27.35) 50.00 (45.35, 54.65) 47.71 (46.14, 49.28) 13.53 (17.85, 27.26) 21.86 (17.42, 25.21) 21.86 (17.42, 25.21) 13.87 (17.42, 25.21) 15.87 (13.87, 19.83) 10.58 (13.67, 15.83) 10.58 (11.53, 15.70) 15.87 (14.56, 10.05) 82.77 (26.72, 31.40) 15.87 (15.30) 15.87 (15.30) 15.87 (15.30) 15.87 (15.30) 15.87 (15.30) 15.87 (15.30) 15.87 (14.56, 16.70) 15.87 (14.57, 17.70) 35.81 (34.47, 35.86) 23.3 (18.75, 52.466) 23.3

Fig. 3. Forest plot of prevalence of anxiety among the public. Note: ^aPrevalence calculated from mean and standard deviation using Monte Carlo simulation.

inclusion of studies conducted only in China found little difference in the prevalence of PTSD and insomnia among healthcare professionals in China (SFigs.18 and 20) the estimates from the main meta-analysis. However, among the public studies conducted solely in China has a lower prevalence of PTSD and insomnia compared the estimates from the main meta-analysis (19.8% vs 23.2% for PTSD and 18.7% vs 23% for insomnia) (SFigs.19 and 21).

The analyses stratified by measurement tool for anxiety, depression, and PTSD among healthcare professionals and the public did not find sufficient evidence for heterogeneity (SFigs. 22, 23, 24, 25, 26, and 27).

The high heterogeneity persisted in the sensitivity analyses that were conducted after removal of studies in which prevalence was computed using simulations of reported mean/median and SD/IQR (SFigs. 28, 29, 30, 31, 32, 33, 34, 35). There was not much difference in the prevalence of anxiety, depression, PTSD, and insomnia among healthcare professionals and anxiety and depression among the public for meta-analyses that included original prevalence estimates and meta-analyses that included both the original and simulated estimates. However, the prevalence was lower in the analysis that included only original prevalence estimates for PTSD (17.1% vs 23.2% for both original and simulated estimates) (SFig. 33) and higher for prevalence of insomnia (28.2% vs 23% for both original and simulated estimates) among the public (SFig. 35).

Stratified analyses by study guality revealed that lower prevalence of anxiety among healthcare professionals for good quality studies (15.6%) (SFig. 36) and significant heterogeneity between good and fair quality studies (P_{heterogeneity} =0.01). Among the public, there was minimal difference in the prevalence of anxiety (fair quality: 23.8% vs good quality: 20.2%); however, study quality could not explain the heterogeneity between the studies (Pheterogeneity =0.18) (SFig. 37). For depression, there was not much difference in the prevalence by study quality among healthcare professionals (SFig. 38) and the public (SFig. 39) with no evidence for heterogeneity by study quality.

3.4. Publication bias

We were able to assess publication bias for prevalence of anxiety, depression, PTSD, and insomnia among both healthcare professionals and the public and alcohol use among the public. Visual inspection of funnel plots indicated publication bias for all these analyses (SFigs. 40, 41, 42, 43, 44, 45, 46, 47, and 48). Egger's test found evidence for publication bias for prevalence estimates of anxiety (bias (SE): 12.8 (2.6), *p* <0.0001), depression anxiety (bias (SE): 11.6 (2.1), *p* <0.0001), PTSD anxiety (bias (SE): 14.4 (5.4), *p* = 0.02), and insomnia anxiety (bias (SE): 21.3 (6.7), p < 0.01) estimates among healthcare professionals. Among the public, Egger's test suggested publication bias for anxiety (bias (SE): 12.6 (4.1), p <0.0001) and insomnia (bias (SE): 13.8 (5.4), p = 0.03) estimates but not for depression (bias (SE): 7.2 (3.7), p = 0.053) and PTSD (bias (SE): 17.9 (18.9), p = 0.36) estimates.

When we examined publication bias by study quality, we found publication bias for studies that were deemed fair and included in the prevalence estimate of both anxiety and depression among the public but not for good quality studies (SFigs. 50, 52). Among healthcare professionals, the publication bias persisted for both good and fair quality studies (SFigs. 49, 51).

3.5. Studies among patients

There were three studies that reported anxiety among COVID-19 patients [22–24]. Hao et al. reported mean (SD) DASS-21 of 6.6 (9) among psychiatric patients and 1.5 (2.7) among healthy controls. Hamm, [24] reported mean PROMIS-anxiety of 57.5 (8) among older adults with MDD. Zhang et al. reported mean GAD-7 score of 10.8 (1.2) among patients of mean age of 42.5 years [22]. Three studies reported mean depression scores - Hao et al. reported mean DASS-21 of 8.3 (10.3) among psychiatric patients and 2.2 (3.5) among healthy controls. Hamm et al. reported mean depression score of 8.7 (5) using PHQ-9 among older adults with MDD. Zhang et al. reported

P. Phiri et al. / EClinicalMedicine 34 (2021) 100806

Author		Percent (95% CI)
AlAteeq, D.A, 2020		24.90 (21.18, 28.92)
Alonso, J, 2020		28.10 (27.18, 29.04)
Antonijevic, J, 2020ª		7.63 (6.40, 9.00)
Arac, S, 2020ª		47.47 (37.34, 57.76)
Azoulay, E, 2020	-	35.44 (28.92, 42.38)
Cai, Q, 2020	_	12.19 (10.37, 14.20)
Chew, N.W.S, 2020ª	•	5.41 (4.03, 7.09)
Chew, S.K, 2021	•	10.00 (6.22, 15.02)
Civantos, A.M., 2020	-	15.95 (10.69, 22.49)
Crowe, S, 2020	=	14.68 (8.63, 22.74)
Das A, 2020		64.45 (59.68, 69.02)
Eweida, R.S, 2020	• •	62.67 (54.40, 70.42)
Florin, M, 2020	•	12.48 (10.85, 14.25)
Francisco, S, 2020ª	•	1.83 (1.00, 3.04)
Giebel C, 2020		20.55 (15.40, 26.51)
Gorini, A, 2020	•	11.38 (9.05, 14.08)
Greenberg, N, 2021	•	21.44 (18.47, 24.65)
Havaei, F, 2021ª		22.01 (20.68, 23.38)
He, Q, 2020		48.64 (43.66, 53.63)
Hong, S, 2021	•	9.40 (8.58, 10.27)
Hummel, S, 2021		17.41 (14.48, 20.66)
Johnson, S.U, 2020	=	14.10 (12.51, 15.81)
Juan, Y, 2020		29.61 (25.45, 34.03)
Judith, A, 2020	•	19.86 (16.95, 23.02)
Kang, L, 2020ª	•	23.64 (21.03, 26.41)
Khanal, P, 2020	•	18.74 (15.33, 22.54)
Lai, J, 2020		50.44 (47.64, 53.24)
Li, X, 2020		46.67 (40.01, 53.41)
Liang, Y, 2020ª	•	11.78 (8.95, 15.12)
Liu, T, 2020ª	• i	4.38 (3.37, 5.57)
Liu, Y, 2021	•	18.44 (16.18, 20.87)
Lu, W, 2020ª		1.08 (0.68, 1.63)
Ma, Y, 2020	+	23.53 (10.75, 41.17)
Magnavita, N, 2020ª	-	37.78 (27.77, 48.62)
Mekonen, E, 2020		55.30 (49.50, 60.99)
Mrklas, K, 2020	i i i i i i i i i i i i i i i i i i i	32.11 (29.68, 34.61)
Naser, A.Y, 2020		20.03 (17.77, 22.45)
Ni, M.Y, 2020		19.16 (14.11, 25.08)
Ning, X, 2020	•	25.00 (21.62, 28.63)
Pan, X, 2020	•	37.63 (30.79, 44.85)
Prasad, A, 2020		22.77 (18.46, 27.55)
Rapisarda, F, 2020 ^a		2.90 (1.18, 5.89)
Rathod, S, 2020	•	7.35 (6.75, 7.99)
Rossi, R, 2020		24.17 (21.91, 26.54)
Sagherian, K, 2020 ^a	•	84.73 (79.03, 89.38)
Sahin, M.K, 2020	•	19.38 (16.90, 22.06)
Saracoglu, K.T, 2020		29.81 (23.68, 36.52)
Shah, N, 2020	۳	15.94 (11.24, 21.65)
Shetchter, A, 2020	· · · · ·	44.86 (38.08, 51.79)
Song, X, 2020		25.20 (24.50, 25.91)
Sun, Y, 2020 ^a		1.49 (0.65, 2.92)
Suryavanshi, N, 2020	•	21.83 (16.27, 28.25)
Than, H.M, 2020	1	20.23 (14.51, 27.00)
Tiete, J, 2020	•	13.29 (10.77, 16.15)
Trumello, C, 2020ª		28.66 (23.72, 34.01)
Wanigasooriya, K, 2020		31.20 (29.43, 33.00)
Woon, L.S.C, 2020	•	5.51 (3.49, 8.23)
Wright, H.M, 2020		20.14 (16.92, 23.67)
Wu, K, 2020ª		51.67 (38.39, 64.77)
Xiaoming, X, 2020	•	3.13 (2.78, 3.52)
Yang, S, 2020	-	11.11 (4.19, 22.63)
Youssef, N, 2020	•	14.81 (11.93, 18.10)
Zhang, C, 2020		50.67 (48.16, 53.18)
Zhang, W-R, 2020 ^a	•	7.61 (6.10, 9.34)
Zheng, R, 2020	•	15.40 (12.64, 18.49)
Zheng, Y, 2021	 ¶	14.49 (10.00, 20.04)
Overall (l ² = 99.5%, p<0.001)	l Y	23.43 (20.59, 26.27)

Fig. 4. Forest plot of prevalence of depression among healthcare professionals. Note: ^aPrevalence calculated from mean and standard deviation using Monte Carlo simulation.

mean PHQ-9 score of 11.7 (1.4). Two studies [22-23] reported insomnia among COVID-19 patients using ISI. Hao et al. found a mean score of 10.1 (7.2) among psychiatric patients and 4.6 (4.0) among healthy controls whereas Zhang et al. found a mean ISI score of 8.7 (1.9) among 30 COVID-19 patients. Other outcomes that were reported among patients were sleep quality, suicidal behavior, COVID-induced psychosis, and death by suicide. Muruganadam [25], reported disturbed but manageable sleep among 26.5% patients and disturbed but unmanageable sleep among 11.4% patients. Xiao [26], reported mean PSQI score of 8.5 (4.5) among 170 patients. Mamun [27], Griffiths [28], reported suicidal behavior among 12 and six patients, respectively, whereas Bhuiyan [29], reported eight deaths

Aharon, A.A, 2021	 49.11 (44.68, 5 	
Ahmed, M.Z, 2020	 37.06 (34.16, 4) 	
Alamri, H.S. 2020 Banna, H.A, 2020	9.64 (8.24, 11.2 57.88 (55.27, 6	90) D. 40)
Bartoszek, A, 2020	22.08 (18.41, 2	
Barzilay, R, 2020	16.00 (14.08, 1	
Bauerle, A, 2020	14.30 (13.76, 1	
Bendau, A, 2020	28.80 (26.61, 3	
Benke, C, 2020	 31.10 (29.72, 3) 	
Brailovskala, J, 2021= Canet-Juric L, 2020+	 14.71 (13.16, 1 6.90 (6.28, 7.57 	
Cansel, N. 2021	8.57 (7.67, 9.54	
Capasso, A, 2021	29.61 (28.44, 3	
Cellini, N, 2020	24.20 (21.90, 2	
Chen, S, 2020	42.88 (41.78, 4	3.99)
Creese, B, 2020	4.85 (4.14, 5.64	
Daly, M, 2020	 11.19 (10.39, 1) 	
Dawel, A, 2020	 9.03 (7.52, 10.7 	
Duong, K.N.C, 2020	23.47 (21.26, 2	
Ettman, C.K, 2020 Every-Palmer, S, 2020	 7.72 (6.82, 8.65 30.30 (28.29, 3) 	9 2 36\
Fancourt, D. 2021	25.10 (24.66, 2	
Faulker, J. 2020	2.07 (1.77, 2.39	
Fisher, J.R.W, 2020	27.60 (26.86, 2	
Fong, B.Y.F, 2020	29.66 (26.00, 3	
Fountoulakis, K.N, 2021	9.30 (8.34, 10.3	
Franceschini, C, 2020	17.01 (16.10, 1	
Fukase, Y, 2021 Gao, J, 2020	18.35 (16.91, 1	
Gab, J, 2020 Garre-Olmo, J, 2021=	48.29 (46.87, 4 3.61 (2.35, 5.25	
Garre-Olmo, J, 2021= Giannopoulou I, 2020=	3.61 (2.35, 5.26	
Giebel C, 2020	13.68 (8.02, 21	
Giuseppe, M.D, 2020	 37.80 (36.53, 3 	
Gonzalez-Sanguino, C, 2020*	11.81 (10.76, 1	2.93)
Guo, Y, 2020	21.32 (19.67, 2	
Hamm, M.E, 2020	19.18 (10.90, 3	
Hazarika, M, 2021	 31.98 (28.06, 3) 59 56 (52.28, 6) 	
He, Q, 2020 Huang, Y, 2020	 58.56 (53.38, 6 20.09 (19.18, 2 	
Huang, T, 2020 Idrissi, A.J. 2020	 20.09 (19.18, 2 35.58 (32.35, 3 	
Jacob, L, 2020	18.94 (14.67, 2	
Jewell, J.S. 2020	28.99 (26.31, 3	
Jiang, W, 2020	 26.71 (26.35, 2 	7.06)
Jung, S, 2020+	 44.94 (43.29, 4) 	
Kar, N. 2021	9.28 (7.28, 11.6	
Kwong, A.S.F, 2020	21.24 (19.76, 2)	
Lechner, W.V, 2020+ Li, S, 2020	24.39 (23.11, 2 4.07 (3.39, 4.83	
Li, 3, 2020 Liang, Y, 2020	8.15 (6.01, 10.7	
Lob, E, 2020	26.08 (25.70, 2	
Lopez-Moreno, M, 2020 ^a	10.55 (7.18, 14	
Lu, C, 2020	 45.70 (42.52, 4) 	
Lu, W, 2020 ^o	0.39 (0.01, 2.15	
Ma, J, 2020+	30.00 (14.73, 4	
Mahamid, F.A. 2021	90.50 (87.19, 9	
Makhashvili, N, 2020 Mamun, M.A, 2021	29.60 (27.65, 3 33.30 (32.38, 3	
Martinotti, G. 2020	16.81 (10.58, 2	
Mazza, C, 2020	11.61 (10.43, 1	
McCracken, L.M, 2020	30.03 (27.46, 3	
McKay, D, 2020*	3.30 (2.24, 4.68)
Mohammadi, S.M, 2021	33.33 (29.05, 3	
Mrklas, K, 2020	43.61 (42.06, 4)	
Naser, A.Y, 2020	16.69 (14.99, 1	
Ni, M.Y, 2020	19.21 (17.30, 2 24.20 (23.28, 2	
Nkire, N, 2021= O'Connor, R.C, 2020	24.20 (23.28, 2 24.70 (23.18, 2	
Odriozola-Gonzalez, P, 2020*	12.41 (11.15, 1	
Omari, O.A, 2020	14.29 (12.23, 1	
Ozdin, S, 2020 ^a	27.41 (22.75, 3	
Pandey, D, 2020	10.18 (8.64, 11)	
Peng, M, 2020*	6.43 (5.07, 8.03	
Pieh, C, 2020*	17.16 (14.17, 2	
Pinkham A, 2020 Puccinelli, P.J. 2021	16.22 (8.67, 26	
Puccinelli, P.J, 2021 Ran, L, 2020	■ 33.33 (21.40, 4 ■ 47.12 (44.77, 4	
Ran, L, 2020 Rathod, S, 2020	 47.12 (44.77, 4) 13.80 (13.01, 1) 	4.62)
Robillard, R, 2021	19.31 (17.83, 2	
Roma P, 2020	 12.30 (9.38, 15 	
Rossi, R, 2020	28.12 (27.52, 2	8.73)
Sediri, S, 2020	20.64 (17.80, 2	
Shah, S.M.A, 2020	14.75 (12.16, 1	
Shermna, A.C, 2020	20.98 (17.77, 2 13.69 (10.99, 1	
Silva, L.R.B, 2020 Skoda, F.M. 2020	■ 13.69 (10.99, 1) 11 65 (10.24, 1)	0.77)
Skoda, E-M, 2020* Smith, B.M, 2020*	 11.65 (10.24, 1) 11.15 (7.70, 15) 	45)
Tan, W, 2020*	4.46 (3.03, 6.30	
Tang, W, 2020	9.00 (7.90, 10.1	
Tee, M.L, 2020	16.92 (15.25, 1	
Thomas, J, 2020	 58.42 (55.36, 6 	1.44)
Tian, F, 2020	 8.40 (6.80, 10.2 	(3)
Traunmuller, C, 2020	27.80 (26.44, 2	
Varma, P, 2020	34.91 (32.61, 3	
Wang Y, 2020	30.01 (28.12, 3	
Wang, C, 2020 (a) Wang, C, 2020 (b) ^a	 16.53 (14.48, 1) 16.86 (15.13, 1) 	
Wang, C, 2020 (b)* Wang, M, 2020	 16.86 (15.13, 1) 17.53 (16.15, 1) 	
Wang, Q, 2020	12.55 (11.16, 1	
Wang, S, 2020	 11.00 (10.56, 1 	1.45)
Winkler, P, 2020	7.68 (6.78, 8.66)
Wu, M, 2020	 47.50 (46.88, 4) 	8.12)
Yang, L. 2020*	6.41 (4.78, 8.39	
Yuan L, 2020+	5.40 (4.68, 6.20	
Zhao, Y, 2020 Zhou, S.J, 2020	29.71 (25.79, 3 43.23 (42.25, 4	
Zhou, S.J. 2020 Overall (I ² = 99.8%, p<0.001)	43.23 (42.25, 4	
	1	

Fig. 5. Forest plot of prevalence of depression among the public. Note: ^aPrevalence calculated from mean and standard deviation using Monte Carlo simulation.

by suicide among COVID-19 patients. Three patients who presented to the emergency medical services with new-onset psychotic symptoms reported COVID-induced psychosis [30].

Synthesizing qualitative studies is growing momentum [31]. Given our large number of cross-sectional studies we used thematic synthesis to identify key themes from included studies. Table 3

provides a list of key emergent themes and in which groups they were prevalent.

4. Discussion

In this systematic review and meta-analysis, we found similar prevalence of anxiety, depression, PTSD, and insomnia among healthcare professionals and the general public, but higher prevalence of suicidal thoughts/ideation or self-harm (11% vs 5.8%) and lower prevalence of wellbeing (28.2% vs 52.6%) among the public compared to healthcare professionals indicative of impact of the pandemic on both physical and mental health of these cohorts. However, in most studies, different rating scales were used to confirm symptoms thereby preventing MH outcomes to be unilaterally confirmed due to the subjectivity the reporting may include. Furthermore, it was generally unclear if any clinical diagnoses were made which could have unreported clinical implications that is difficult to predict. In relation to HCPs, it remains unclear if these were both frontline and nonfrontline staff. Similarly, a breakdown of the staffing categories were not reported, this would be vital for both clinical and service delivery decision making associated with occupational burnout, resources and meeting capacity to demand would be based on some of these factors

Based on the findings, it appears, the general public may have had challenges with their mental health. However, it remains to be seen those who contracted COVID-19 versus those who didn't and the mental health implications across these 2 groups. Similarly, it remains unclear, of the general public that took part in these studies, those who were tested for covid-19 with a negative result versus the opposite as this would further alter the clinical significance and implications surrounding the mental healthcare needs. Since most cross-sectional studies included in this study do not appear to have longitudinal data, this further purports the need for comprehensive longitudinal research to be conducted to evaluate the long-term MH impact of COVID-19 on patients, HCPs and the general public as well as the healthcare systems. Equally, it would be important to understand any potential comorbidities associated with the HCPs, patients and the general public, as these underlying conditions could further exacerbate the MH impact determined. As a result, it could be said, a bi-directional relationship could exist between the reported as well as perceived MH impact and the psychosocial dynamics that could influence even cultural paradigms that are deterrents of social constructs.

These findings show some consistency with several other systematic reviews and editorials published. Three systematic reviews published reports on the prevalence of anxiety and depression within the general public [32-34] which are the two most common indicators of psychological impact reported in our systematic review. The prevalence rate of anxiety and depression symptoms was 33% and 28%, respectively, in Luo et al. [32] and 31.9% and 33.7% in Salari et al. [33], with these findings being consistent with the current systematic review that indicated a pooled prevalence of 22.4% for anxiety and 22.6% for depression in the general public. Furthermore, all quantitative studies included in Luo et al. review were cross-sectional surveys or cohort studies, which is consistent with the type of publications included within the current systematic review. However, the review [34] showed noticeable variation in the prevalence of anxiety ranging from 6.33 to 50.9% and depression ranging from 14.6% to 48.3%. The variation in prevalence rates from across the 19 studies included could have been due to the various measurement scales used, plus also potential cultural differences towards mental health and reporting patterns. An additional review by Sheraton et al. [35] reported higher incidence of insomnia within healthcare professionals during COVID-19 which is similar to the reports of insomnia in the healthcare professionals included in this current review. However, this




Fig. 6. Forest plot of prevalence of post-traumatic disorder among (A) healthcare professionals and (B) the public. Note: ^aPrevalence calculated from mean and standard deviation using Monte Carlo simulation.

review consisted of only 14 publications and was not specific to mental healthcare professionals. gathered over a 3 week period demonstrated a comparison of HCPs and non-HCPs self-reporting higher proportion of mild depression and anxiety. A snapshot to the current psychological state of HCPs of similar increases in the prevalence rate of depression, anxiety and

Our review found consistently higher levels of distress in healthcare workers and echoes studies such as Rathod et al. [2] where data

Table 3

Themes.

Themes		Population Groups		
	General Public (<i>n</i> = 60%)	Healthcare Professionals ($n = 35\%$)	Mental Health Patients (<i>n</i> = 5%)	
Anxiety	++++++++++++++++++++++++++++++++++++++	••••••	+++++	
Depression	++++++++++++++++++++++++++++++++++++++	++++++++++++++++++++++++++++++++++++++	++++++	
Sleep disruption/quality	*****	++++++++++++	+++	
PTSD	*****	+++++++++++++++++++++++++++++++++++++++	+	
Insomnia	+++++++++++++++++++++++++++++++++++++++	+++++++++++++++++++++++++++++++++++++++		
Well-being	+++++++++++++++++++++++++++++++++++++++	+++++		
Suicide/Suicidal behavior	+++++++++++++++++++++++++++++++++++++++	++++	++	
Stress	++++++++++	++++++		
Alcohol consumption	+++++++++	+	+	
Physical Activity	++++++	+		
Substance Abuse	++++	+	++	
Fear	++++	+	+	
OCD	++++	++	Ŧ	
Gender Differences	++++	TT		
Loss of work	+++			
Psychotic Symptoms	+	+	+	
Isolation	++	Ŧ	+	
	+		+	
Psychosis	+		+	
Persecution			+	
Risk Perception	+			
Headache		+		
Overwhelming Workload		+		
Quality of Life		+		
Life Stressors		+		
Disgust	+			
Knowledge surrounding COVID-19			+	
Murder-suicide	+			
Starvation	+			
Psychosis post COVID infection			+	
Economic Status	+			
Social Support	+			
Infodemia	+			
Rumination	+			
Diet	+			
Trauma		+		
Religion	+			
Workplace violence		+		

sleep disturbances has been provided by Ho et al. [36] and Ali et al. [37].

It is evident, the imperative role of the global healthcare systems are playing in trying to maintain high quality care levels to patients and the general public. As a consequence of this, HCP's own MH and wellbeing has been impacted negatively. To resolve this, several hospitals for example in China that were greatly impacted by COVID-19 implemented a three-staged method to care for the psychological wellbeing of staff. The approach involved development of online courses, a hotline team that provided supervision and guidance to callers with psychological problems, and interventions that aim to alleviate stress [38]. Similar approaches could be used by other healthcare systems. Acceleration of digital platforms and tele-psychiatry due to the pandemic provide opportunities to adapt more pandemic preparedness interventions and services including popular health apps to combat the combat the surge in mental health problems. Two apps support by UKRI through the Industrial Strategy Challenge Fund, Sleepio and Daylight apps are specific for NHS workers designed to maintain sleep efficiency, reduce anxiety symptoms and to address mental health issues by providing healthcare workers evidence-based techniques [39-40].

It is equally important to use a 'lessons learnt' approach, for example with previous studies outbreaks such as the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) that showed adverse psychological impacts on HCPs. Their MH outcomes were high levels of anxiety, depression, and stress that resulted in many HCPs having post-traumatic stress disorder [41–42]. These findings have a direct correlation with another recent study exploring the impact of COVID-19 that highlighted a considerable proportion of HCPs in China experiencing a high level of anxiety and depression, insomnia and psychological distress [43]. The metaanalysis of this study further affirms these findings. HCPs in locations affected by pandemics are prone to symptoms of anxiety and depression long term [44]. It is unclear whether these findings are generalizable to the UK for example, but it is worth considering conducting research to implement any preventative strategies for future populations.

Based on our thematic and narrative synthesis, patients admitted to critical care for example, with ARDS experienced higher levels of anxiety (40%), depression (30%) and PTSD (20%) symptomatologies [45]. This is asserted by Bauerle and colleagues [46] study that demonstrated similar findings along with psychological stress within the general population. Another recent survey of patients which compared those with a previous history of a mood disorder with those with no previous or current mental disorders found that psychological distress was elevated, with the highest level of depression and stress in those with bipolar disorder [47]. On the other hand, psychosis and recurrence of more longstanding MH problems are rarer based on current data. Sleep disturbance is common in critically ill patients up to 12 months after hospital discharge, with prevalence ranging between 10 and 60% at six months [48] although this association in the current pandemic can only be hypothesized given the lack of data available. Both subjective and objective studies, however, suggest that sleep disturbance improves over time. Although, this crosssectional work will require further elaboration in longitudinal studies to confirm the generalizability of these findings.

Additionally, social media in general has inevitably created fear and stress around being infected by COVID-19. Whilst, this could impact those with existing MH disorders significantly, obsessive compulsive disorder (OCD) patients in particular, have had an increase in the symptomatologies since the start of lockdown. In particular, those who displayed contamination symptomatologies prior to the start of the pandemic experienced a worsening during lockdown [49]. It is further reported, people living with schizophrenia could be at increased risk due to a potential lack of insight and poorer decision-making abilities, which could result in difficulties adopting necessary protective measures [50]. This could attribute to an increase in covid-19 incidence and/or transmission rates. Therefore, considerations should be made to preventing relapse or worsening of symptomatologies in those with MH disorders if lockdown and/or self-isolation measures are introduced in the future. Strategies such as remote monitoring of symptomatologies using tele-psychiatry method for example could be useful. Additionally, the use of online psychological intervention tools may be of benefit to those with acute mental wellbeing issues although, where possible, clinicians could provide recommendations for those with an existing clinical diagnoses as well [51]. Undoubtedly, some patients may prefer face to face appointments to remote consultations, whilst others may find the reduced wait and travelling time to be advantageous [52]. Between consultations, text messaging has been found to be an effective way of improving engagement with clinical services [53] and may be useful for HCPs in particular to consider in the current climate.

Another facet to consider are patients recovering from COVID may have ongoing difficulties with any of their daily activities, including personal care, domestic tasks, leisure activities and instrumental activities of daily living [54] which could impact their MH. Based on the evidence of this study, there appears to be a lack of data associated with this aspect and is a knowledge gap that should be addressed by way of conducting research that could include these participants as well.

The evidence indicates that there are a number of unilateral mental health issues to consider and therefore, healthcare systems would need to manage their capacity to demand with caution. MH provision remains a challenge for example in the UK, where the NHS has had various challenges to cater to growing demand. Whilst improvement in MH services are a priority as reported in the NHS long-term plan in the UK, the inadvertent impact of the pandemic would only foster a sense of urgency to address the service issues [55]. Depression and anxiety affect 15-20% of the adult population at any one time and has huge personal and economic burden [56] and a major contributor to suicide [57]. It is evident that the pandemic has exacerbated the presentation of these issues. Although the current pandemic represents a national and global challenge, it also presents opportunities for how the NHS and other healthcare systems initiate better ways to deliver critical care and interventions remotely where possible, and bringing forth a new era in healthcare access. Use of tele-psychiatry and its effectiveness [58] in the UK in particular, warrants further investigation [59] to curb future pandemics. When considering the psychological impact on HCPs and frontline staff, it is crucial for novel psychological interventions to become more adaptable for use in digital platforms such as virtual and augmented reality (VR/AR) [60-63] for ease of access by a busy clinical workforce. With serious workforce shortages currently in global MH services in particular, further resource losses should be prevented. Therefore, the findings from this review should inform policy, training and service development and implementation to move towards a more integrated care model.

To our knowledge, this is the first systematic review and metaanalysis to examine the psychosocial and MH impact taking into consideration, physical symptomatologies as well across 3 cohorts. The number of studies that met the eligibility criteria for inclusion into the meta-analysis was relatively low, although a total of 103,097 subjects were involved in the current review. This does provide a much higher N and demonstrates a statistical significance prompting a call for further longitudinal research to be conducted. We conducted a thorough literature search in several databases, and the results of the current systematic review reinforce the high relevance and importance of considering MH outcomes across various cohorts when developing clinical and public health measures. The extraction of information from each study adhered to the refinement protocol, with this current review being the only study thus far during the pandemic to utilize such a method.

This review does not come without certain limitations. Firstly, all the quantitative studies included were cross-sectional with very limited follow-up, if any. Due to the cross-sectional nature of the included studies, there would only be a limited comparison of results. In addition, the studies included within the current review use a variety of instruments to measure the psychological impact of COVID-19 on specified variables (e.g. depression and anxiety, among others). None of the studies conducted in-person surveys and standardized clinical interviews to diagnose participants; therefore, there remains a question whether subjects had sub-threshold symptomatologies and/or clinically diagnosed disorders. A variety of instruments were used to measure anxiety and depression among the public, whereas among HCPs, anxiety was mainly measured using GAD-7 and PHQ-9 was used for depression. This could be a factor in the differences seen in the prevalence estimates between these populations. We were also limited by the number of studies that could be included in the subgroup analysis. Moreover, the variation in countries where the studies were conducted was limited. Due to the outbreak of COVID-19 being observed first in China, 48% of the studies include originated from there. Also, with the inclusion of studies solely written in the English language, this may have introduced further publication bias. Another limitation is that due to the inability to synthesize evidence from studies that reported mental health outcomes among COVID-19 patients, comparisons were not possible between the outcomes among patients and healthcare professionals and the public. Finally, even though we conducted sensitivity analyses to examine sources of heterogeneity by age, country, outcome measurement tool, study quality, and after removal of studies in which prevalence was computed using simulations of reported mean/median and SD/IQR we found insufficient evidence to explain this high heterogeneity. The only exceptions being age as a significant predictor of heterogeneity for depression among the public and study quality for anxiety among healthcare professionals. A possible reason for the high heterogeneity is that these estimates are for healthcare professionals as a whole and the general public in total. However, healthcare professionals consist of a group of individuals from different professions and occupations. Similarly, members from the public are comprised of individuals from different backgrounds, living and working in different environments, and having a wide range of physical, mental, and emotional health. Additionally, there may be methodological differences between the studies that we were unable to investigate. Though we used random effects models to pool the estimates of prevalence the presence of such high heterogeneity indicates that the results from the meta-analysis should be interpreted with caution.

The direct and indirect psychosocial impact of the Covid-19 pandemic is evident and could have long-term effects, more so in light of long COVID [64]. Whilst the prevalence of the MH symptomatologies and their exacerbation enforces a MH impact, these could be different in various sub-groups and there could be underlying mechanistic triggered responses as a result of exposure to the direct and indirect effects of COVID-19 may including adverse effects on brain function as suggested by Holmes and colleagues [65]. The requirement for distinguishing the difference between symptomatologies and diagnosed conditions should be considered as a priority for future research conducted to determine the MH impact due to COVID-19. The requirement for distinguishing the difference between symptomatologies and diagnosed conditions should be considered at the time of designing the study and reporting the results as well as the publication stage by all parties involved. Given the significant impact of COVID on Black, Asian Minority Ethnic (BAME) groups [66], studies exploring role of ethnicity are warranted. Additionally, core outcome-based reporting methods should be considered by researchers as this would aid in interpreting the data in a unified manner in the future. Furthermore, researchers, funders and policy makers should deploy studies to evaluate the psychosocial and neuroscientific effects of the pandemic using longitudinal studies to mobilize better infrastructure to

manage infection and lockdown for healthcare professionals, patients and the general public. Whilst it is important to propose frameworks and policies for prioritization of developing this research further, it is vital to have multidisciplinary approaches to effectively address the ongoing and future mental healthcare needs of the global population.

Declaration of Competing Interest

PP has received research grant from Novo Nordisk, and other, educational from Queen Mary University of London, other from John Wiley & Sons, other from Otsuka, outside the submitted work. SR reports other from Janssen, Lundbeck and Otsuka outside the submitted work. All other authors report no conflict of interest.

The views expressed are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care or the Academic institutions.

Data sharing statement

The authors declare that the data collected was gathered from publicly available studies and is available upon reasonable request. Request should be made to the corresponding author

Funding

KE, GD, and PP are supported by National Institute for Health Research (NIHR) Research Capability Funding (RCF) and by Southern Health NHS Foundation Trust and Oxford Brain Health Clinical Trials Unit. All of the study sponsors had no further role in the study design, data collection, analysis and interpretation of data; in the writing of the report and in the decision to submit the paper for publication

Contribution of each author

PP and GD developed study design and wrote the first draft of the manuscript. KE, TT, GD and SA-Y conducted database searches and study selection and data extraction. RR performed statistical analyses and contributed to the results' section. GD, RR, KE, VR, TT, SR, DK, SWC, OWW, EKW, SSC, NS, NH, SA-Y and PP critically reviewed and revised the manuscript. All authors approved the final version of the manuscript.

Acknowledgements

The authors acknowledge support from Southern Health NHS Foundation Trust and Oxford Brain Health Clinical Trials Unit.

This paper is part of the multifaceted EPIC project that is sponsored by Southern Health NHS Foundation Trust and in collaboration with the University of Oxford's Oxford Brain Health Clinical Trials Unit and The Chinese University of Hong Kong.

We would like to acknowledge Dr Mustafa Soomro for his contribution and valuable comments to the SR protocol.

Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.eclinm.2021.100806.

References

- [1] Cenat JM, Blais-Rochette C, Kokou-Kpolou K, Noorishad PG, Mukunzi JN, McIntee SE, Dalexis RD, Goulet MA, Labell PR. Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: a systematic review and metaanalysis. Psychiatry Res 2021;295(113599). doi: 10.1016/j.psychres.2020.113599.
- [2] Rathod S, Pallikadavath S, Young AH, Graves L, Rahman MM, Brooks A, Soomro M, Rathod P, Phiri P. Psychological impact of COVID-19 pandemic: protocol and

results of first three weeks from an international cross-section survey – focus on health professionals. J Affect Disord Rep 2020:100005. doi: 10.1016/j. jadr.2020.100005.

- [3] National Health Service. NHS staff survey results. Oxford: NHS Survey Coordination Centre; 2019.
- [4] British Medical Association. (2020) COVID-19: analyzing the impact of coronavirus on doctors. https://www.bma.org.uk/advice-and-support/covid-19/what-thebma-is-doing/covid-19-analysing-the-impact-of-coronavirus-on-doctors
- [5] Wu P, Fang Y, Guan Z, et al. The psychological impact of the SARS epidemic on hospital employees in China: exposure, risk perception, and altruistic acceptance of risk. Can J Psychiatry 2013;54(5):302–11.
- [6] Phiri P, Rathod S, Elliot K, Delanerolle G. The Impact of COVID-19 on the mental wellbeing of healthcare staff. EJPMR 2020;7(8):66–71.
- [7] Marshall RD, Galea S, Kilpatrick D. Psychaitric consequences of September 11. JAMA 2002;288(21):2683–4.
- [8] Marshall RD, Bryant RA, Amsel L, Suh EJ, Cook JM, Neria Y. The psychology of ongoing threat: relative risk appraisal, the September 11 attacks, and terrorismrelated fears. Am Psychol 2007;62(4):304–16.
- [9] Neira Y, DiGrande L, Adams BG. Posttraumatic stress disorder following the September 11, 2001, terrorist attacks. Am Psychol 2011;66(6):429–46.
- [10] Jiang HJ, Nan J, Lv ZY, Yang J. Psychological impacts of the COVID-19 epidemic on Chinese people: exposure, post-traumatic stress symptoms, and emotion regulation. Asian Pac J Trop Med 2020;13(6):252–9.
- [11] Steardo L, Steardo L, Zorec R, Verkhratsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19. Acta Physiol 2020;229 (3):e13473. (Oxf). doi: 10.1111/apha.13473.
- [12] Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol 2020;215:108427. doi: 10.1016/j.clim.2020.108427.
- [13] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395 (10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
- [14] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Wang C. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 2020;382(19):1787– 99. doi: 10.1056/NEJMoa2001282.
- [15] Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. Int J Antimicrob Agents 2020:105949. doi: 10.1016/j.ijantimicag.2020.105949.
- [16] Horby PW, Landray MJ. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial. Lancet 2020;396:1345-52 October 5, 2020. doi: 10.1016/S0140-6736(20)32013-4.
- [17] WHO Coronavirus Disease (COVID-19) Dashboard. Retrieved from https:// covid19.who.int/ 2020
- [18] Wells G, Shea B, O'Connel D, Peterson J, Welch V, Loso M, Tugwell P. The newcastle-ottawa scale (Nos) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, ON, Canada: Ottawa Hospital Research Institute; 2000.
- [19] Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, Perruolo E, Parati G, ESH Working Group on CV Risk in Low Resource Settings. Panethnic differences in bloody pressure in Europe: a systematic review and meta-analysis. PLoS ONE 2016;11(1):e0147601. doi: 10.1371/journal.pone.0147601.
- [20] Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5(13). doi: 10.1186/1471-2288-5-13.
- [21] Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557–60.
- [22] Zhang H, Qin S, Zhang L, Feng Z, Fan C. A psychological investigation of coronavirus disease 2019 (COVID-19) patients in mobile cabin hospitals in Wuhan. Ann Transl Med 2020;8(15):941. doi: 10.21037/atm-20-4907.
- [23] Hao F, Tan W, Jiang L, Zhang L, Zhao X, Zou Y, Hu Y, Luo X, Jiang X, McIntyre RS, Tran B, Sun J, Zhang Z, Ho R, Ho C, Tam W. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A casecontrol study with service and research implications for immunopsychiatry. Brain Behav Immun 2020;87:100–6. doi: 10.1016/j.bbi.2020.04.069.
- [24] Hamm ME, Brown PJ, Karp JF, Lenard E, Cameron F, Dawdani A, Lavretsky H, Miller JP, Mulsant BH, Pham VYT, Reynolds CF, Roose SP, Lenze EJ. Experiences of American older adults with pre-existing depression during the beginnings of the COVID-19 pandemic: a multicity, mixed-methods study. Am J Geriatr Psychiatry 2020;28(9):924–32. doi: 10.1016/j.jagp.2020.06.013.
- [25] Muruganandam P, Neelamegam S, Menon V, Alexander J, Chaturvedi SK. COVID-19 and severe mental illness: impact on patients and its relation with their awareness about COVID-19. Psychiatry Res 2020;291:113265. doi: 10.1016/j.psychres.2020.113265.
- [26] Xiao H, Zhang Y, Kong D, Li S, Yang N. Social capital and sleep quality in individuals who self-isolated for 14 days during the coronavirus disease 2019 (COVID-19) outbreak in January 2020 in China. Med Sci Monit Int Med J Exp Clin Res 2020;26: e923921. doi: 10.12659/MSM.923921.
- [27] Mamun MA, Ullah I. COVID-19 suicides in Pakistan, dying off not COVID-19 fear but poverty? – the forthcoming economic challenges for a developing country. Brain Behav Immun 2020;87:163–6. doi: 10.1016/j.bbi.2020.05.028.
- [28] Griffiths MD, Mamun MA. COVID-19 suicidal behaviour among couples and suicide pacts: case study evidence from press reports. Psychiatry Res 2020;289:113105. doi: 10.1016/j.psychres.2020.113105.
- [29] Bhuiyan A, Sakib N, Pakpour AH, Griffiths MD, Mamun MA. COVID-19-related suicides in Bangladesh due to lockdown and economic factors: case study evidence from media reports. Int J Ment Health Addict 2020:1–6 Advance online publication. doi: 10.1007/s11469-020-00307-y.

- [30] Ferrando SJ, Klepacz L, Lunch S, Tavakkoli M, Dornbush R, Baharani R, Smolin Y, Bartell A. COVID-19 Psychosis: a potential new neuropsychiatric condition triggered by novel coronavirus infection and the inflammatory response? Psychosomatics 2020;61(5):551–5. doi: 10.1016/j.psym.2020.05.012.
- [31] Tomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol 2008;8(45). doi: 10.1186/1471-2288-8-45.
- [32] Luo M, Guo L, Yu M, Jiang W, Wang H. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public – a systematic review and meta-analysis. Psychiatric Res 2020;291:113190. doi: 10.1016/j.psychres.2020.113190.
- [33] Salari N, Hosseinian-Far A, Jalali R, Vaisi-Raygani A, Rasoulpoor S, Mohammadi M, Rasoulpoor S, Khaledi-Paveh B. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Glob Health 2020;16:57. doi: 10.1186/s12992-020-00589-w.
- [34] Xiong J, Lipsitz O, Nasri F, Lui L, Gill H, Pphan L, Chen-Li D, lacobucci M, Ho R, Majeed A, McIntyre RS. Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord 2020;277:55–64. doi: 10.1016/j.jad.2020.08.001.
- [35] Sheraton M, Deo N, Dutt T, Surani S, Hall-Flavin D, Kashyap R. Psychological effects of the COVID-19 pandemic on healthcare workers globally: a systematic review. Psychiatry Res 2020;292:113360. doi: 10.1016/j.psychres.2020.113360.
- [36] Ho CS, Chee CY, Ho RC. Mental health strategies to combat the psychological impact of COVID-19 beyond paranoia and panic. Ann Acad Med Singap 2020;49:155–60 pmid http://www.ncbi.nlm.nih.gov/pubmed/32200399.
- [37] Ali S, Maguire S, Marks E, Doyle M, Sheehy C. Psychological impact of the COVID-19 pandemic on healthcare workers at acute hospital settings in the South-East of Ireland: an observational cohort multicenter study. BMJ Open 2020;10: e042930. doi: 10.1136/bmjopen-2020-042930.
- [38] Chen Q, Liang M, Li Y, Guo J, Fei D, Wang L, He L, Sheng C, Cai Y, Li X, Wang J, Zhang Z. Mental health care for medical staff in China During the COVID-19 outbreak. Lancet 2020;7(4). doi: 10.1016/S2215-0366(20)30078-X.
- [39] UKRI. (2020). Apps to help distancing and NHS staff. Available: https://www.ukri. org/our-work/tackling-the-impact-of-covid-19/addressing-technological-challenges/apps-to-help-distancing-and-nhs-staff/. Last accessed 23rd Feb 2021
- [40] Rodriguez, A. (2020). Sleepio might be just what the professor ordered. Available: https://medicalxpress.com/news/2020-10-sleepio-professor.html. Last accessed 23rd Feb 2021
- [41] Lee SM, Kang WS, Cho A-R, Kim T, Park JK. Psychological impact of the 2015 MERS outbreak on hospital workers and quarantined hemodialysis patients. Compr Psychiatry 2018;87:123–7. doi: 10.1016/j.comppsych.2018.10.003.
- [42] Tam CWC, Pang EPF, Lam LCW, Chiu HFK. Severe acute respiratory syndrome (SARS) in Hong Kong in 2003: stress and psychological impact among frontline healthcare workers. Psychol Med 2004;34:1197–204.
- [43] Lai J, Ma S, Wang Y, Cai Z, Hu J, Wei N, Wu J, Du H, Chen T, Li R, Tan H, Kang L, Yao L, Huang M, Wang H, Wang G, Liu Z, Hu S. Factors associated with mental health outcomes among health care workers exposed to coronavirus disease 2019. JAMA Netw Open 2020;3:e203976. doi: 10.1001/jamanetworkopen.2020.3976.
- [44] Chong MY, Wang WC, Hsieh WC, et al. Psychological impact of severe acute respiratory syndrome on health workers in a tertiary hospital. Br J Psychiatry 2004;185:127–33.
- [45] Bienvenu OJ, Colantuoni E, Mendez-Tellez PA, Shanholtz C, Dennison-Himmelfarb CR, Pronovost PJ, Needham DM. Co-occurrence of and remission from general anxiety, depression, and posttraumatic stress disorder symptoms after acute lung injury: a 2-year longitudinal study. Crit Care Med 2015;43(3):642–53. doi: 10.1097/CCM.00000000000752.
- [46] Bäuerle A, Teufel M, Musche V, Weismüller B, Kohler H, Hetkamp M, Dörrie N, Schweda A, Skoda EM. Increased generalized anxiety, depression and distress during the COVID-19 pandemic: a cross-sectional study in Germany. J Public Health 2020:fdaa106. (Bangkok). doi: 10.1093/pubmed/fdaa106.
- [47] Van Rheenen TE, Meyer D, Neill E, et al. Mental health status of individuals with a mood-disorder during the COVID-19 pandemic in Australia: initial results from the COLLATE project [published online ahead of print. J Affect Disord. 2020;2020 (275):69–77. doi: 10.1016/j.jad.2020.06.037.
- [48] Altman MT, Knauert MP, Pisani MA. Sleep disturbance after hospitalization and critical illness: a systematic review. Ann Am Thorac Soc 2017;14(9):1457–68. doi: 10.1513/AnnalsATS.201702-148SR.
- [49] Davide P, Andrea P, Martina O, Andrea E, Davide D, Mario A. The impact of the COVID-19 pandemic on patients with OCD: effects of contamination symptoms and remission state before the quarantine in a preliminary naturalistic study. Psychiatry Res 2020;291:113213 Advance online publication. doi: 10.1016/j.psychres.2020.113213.
- [50] Kozloff N, Mulsant BH, Stergiopoulos V, Voineskos AN. The COVID-19 global pandemic: implications for people with schizophrenia and related disorders. Schizophr Bull 2020;46(4):752–7 VolumeIssuePages. doi: 10.1093/schbul/sbaa051.
- [51] Hulsbosch AM, Nugter MA, Tamis P, Kroon H. Videoconferencing in a mental health service in the Netherlands: a randomized controlled trial on patient satisfaction and clinical outcomes for outpatients with severe mental illness. J Telemed Telecare 2017;23(5):513–20.
- [52] Thiyagarajan A, Grant C, Griffiths F, Atherton H. Exploring patients' and clinicians' experiences of video consultations in primary care: a systematic scoping review. BJGP Open 2020;4(1) bjgpopen20×101020. doi: 10.3399/bjgpopen20×101020.
- [53] D'Arcey J, Collaton J, Kozloff N, Voineskos AN, Kidd SA, Foussias G. The use of text messaging to improve clinical engagement for individuals with psychosis: systematic review. JMIR Ment Health 2020;7(4):e16993.

- [54] England.nhs.uk. (2020). Aftercare needs of inpatients recovering from COVID-19. Retrieved from https://www.england.nhs.uk/coronavirus/wp-content/uploads/ sites/52/2020/06/C0705-aftercare-needs-of-inpatients-recovering-from-covid-19-aug-2020.pdf
- [55] NHS. (2019). The NHS long term plan. Available:https://www.longtermplan.nhs. uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pdf. [Last accessed: 25th Feb 2021]
- [56] Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 2015;76(2):155–62. doi: 10.4088/JCP.14m09298.
- [57] Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 2014;13(2):153–60. doi: 10.1002/ wps.20128.
- [58] Palylyk-Colwell E, Argaez C. Telehealth for the assessment and treatment of depression, post-traumatic stress disorder, and anxiety: clinical evidence. Ottawa: CADTH; (CADTH Rapid Response Report: Summary with Critical Appraisal); 2018.
- [59] Carlbring P, Andersson G, Cuijpers P, Riper H, Hedman-Lagerlof E. Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: an updated systematic review and meta-analysis. Cogn Behav Ther 2018;47 (1):1–18. doi: 10.1080/16506073.2017.1401115.
- [60] Judd T, Aquilina AL, Hunter I. Virtual reality medical training: a non-inferiority randomized controlled trial of VR vs face-to-face training. J Med Educ Train 2020;4:044.
- [61] Shiban Y, Schelhorn I, Pauli P, Muhlberger A. Effect of combined multiple contexts and multiple stimuli exposure in spider phobia: a randomized clinical trial in virtual reality. Behav Res Ther 2015;71:45–53. doi: 10.1016/j.brat.2015.05.014.

- [62] Didehbani N, Allen T, Kandalaft M, Krawczyk D, Chapman S. Virtual reality social cognition training for children with high functioning autism. Comput Hum Behav 2016;62:703–11.
- [63] Saposnik G, Redelmeier D, Ruff CC, Tobler PN. Cogntive biases associated with medical decisions: a systematic review. BMC Med Inform Decis Mak 2016;16 (138).
- [64] Iqbal SZ, Li B, Onigu-Otito E, Naqvi MF, Shah AA. The long-term mental health effects of COVID-19. Psychiatr Ann 2020;50(12):522–5. doi: 10.3928/00485713-20201103-01.
- [65] Holmes EA, O'Connor RC, Perry VH, Tracey I, Wessely S, Arseneault L, Ballard C, Christensen H, Silver RC, Everall I, Ford T, John A, Kabir T, King K, Madan I, Michie S, Przbylski AK, Shafran R, Sweeney A, Worthman CM, Yardley L, Cowan K, Cope C, Hotopf M, Bullmore E. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry 2020;7 (6):547–60. doi: 10.1016/S2215-0366(20)30168-1.
- [66] Phiri P, Delanerolle G, Al-Sudani A, Rathod S. COVID-19 and black, Asian, and minority ethnic communities: a complex relationship without just cause. JMIR 2020;7(2). doi: 10.2196/22581.
- [67] Delanerolle G, Phiri P, Soomro M, Raymont V, Elliot K, Rathod S. A systematic review of evaluating the psychosocial impact of the COVID-19 pandemic on patients, general public and mental healthcare professionals. PROSPERO 2020:1– 7 CRD42020181481 Available from https://www.crd.york.ac.uk/prospero/dis play_record.php?ID=CRD42020181481.